+关注
titeufakina
暂无个人介绍
IP属地:未知
80
关注
1
粉丝
4
主题
0
勋章
主贴
热门
titeufakina
2020-11-29
Great ariticle, would you like to share it?
@话题虎:【话题】巴菲特卖苹果,重金出击疫苗股!虎友们,跟不跟?
titeufakina
2020-11-27
Great ariticle, would you like to share it?
@七仙子:7天翻了一倍多,我是如何抓住这只黑马的?
titeufakina
2020-11-27
Great ariticle, would you like to share it?
@话题虎:【话题】巴菲特卖苹果,重金出击疫苗股!虎友们,跟不跟?
titeufakina
2020-11-27
Great ariticle, would you like to share it?
@小虎说英股:Regal Cinemas Owner in Talks for Rescue Package
titeufakina
2020-11-26
Great ariticle, would you like to share it?
@牧财鲸_踩不到热点版:分享7个我最常用的美股研究网站。包括筛选器,财报,期权,ETF,IPO,做空,应有尽有。而且免注册!
titeufakina
2020-11-26
Great ariticle, would you like to share it?
@阳光财经: 美股分析2021年风险前瞻:美股估值历史最高位!2021年会不会迎来系统性风险?
titeufakina
2020-11-23
Great ariticle, would you like to share it?
@爱投学院:大疫情背景下,中概股简直是独领风骚。曾经被大部分人不看好的二次元小破站,如今也崛起成为了多媒体平台帝国了。想知道这是哪只巨大的潜力股吗,点开视频看看吧!$哔哩哔哩(BILI)$ $谷歌(GOOG)$ $阿里巴巴(BABA)$ 公司于今日发布了未经审计的三季报,营收32.3亿元,同比增长74%,超出预期!本季度,用户日均视频播放量达到创记录的13亿次,同比提升77%。随着社区参与度的持续走高,用户日均使用时长高达81分钟。本季度月均付费用户数同比增长89%达1500万,期待未来的盈利能力不断提升。公司对2020年第四季度收入进行了展望,预计将达到36.0亿元至37.0亿元人民币。爱投学院与老虎联合推出最畅销北美投资课程,北美专家手把手教你分析,授之以渔,把财富增值掌握在自己手中。无论美股、港股还是A股,这些经验和方法都非常适用。快来感受原汁原味的北美独立观点,和我们踏上财富自由的旅程。
titeufakina
2020-11-23
Great ariticle, would you like to share it?
@桃李春风益点财:这次疫苗真的要来了。昨夜,Moderna$Moderna, Inc.(MRNA)$ 宣布,他们研发的疫苗有效率高达94.5%。上周,辉瑞$辉瑞(PFE)$ 公司和德国生物技术公司BioNTech$BioNTech SE(BNTX)$ 表示,他们的疫苗在预防新冠方面的效果超过90%,比普通流感疫苗70%的有效率足足高出20%!疫苗捷报频传,这是否意味着我们翘首以盼的疫苗即将问世?疫苗分发的时间表出来了吗?其安全性和有效性方面是否让人放心?对于这几个问题,我们采访了The Pinea Group 的 CEO 和首席执行官马蓓女士。
titeufakina
2020-11-23
Great ariticle, would you like to share it?
@三藏的财富频道: 与大家一起复盘一下ARK对冲基金的投资报告复盘,抄作业的朋友看过来~大家喜欢三藏的视频不要忘记关注,点赞加评论哦! 感谢大家! $Ark Fintech Innovation ETF(ARKF)$ $Ark Restaurants Corp(ARKR)$ $ARK Web x.0 ETF(ARKW)$
titeufakina
2020-11-22
Great ariticle, would you like to share it?
@美股研究社:股神“偏爱”这三只股,投资者该“抄作业”吗?
titeufakina
2020-11-22
Great ariticle, would you like to share it?
Novartis signs $50 mln deal for Mesoblast cell therapy for COVID, beyond
titeufakina
2020-11-22
Great ariticle, would you like to share it?
抱歉,原内容已删除
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3568479083861646","uuid":"3568479083861646","gmtCreate":1605385061552,"gmtModify":1605385061552,"name":"titeufakina","pinyin":"titeufakina","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":80,"tweetSize":12,"questionSize":0,"limitLevel":999,"accountStatus":2,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖(非转发)","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":4,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":3,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.31","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":391879094,"gmtCreate":1606599136318,"gmtModify":1703843685505,"author":{"id":"3568479083861646","authorId":"3568479083861646","name":"titeufakina","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3568479083861646","idStr":"3568479083861646"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/391879094","repostId":"390064684","repostType":1,"repost":{"id":390064684,"gmtCreate":1605672840142,"gmtModify":1703838916404,"author":{"id":"3502767768442965","authorId":"3502767768442965","name":"话题虎","avatar":"https://static.tigerbbs.com/d418c2def5dc1d094b03270b450f71ce","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3502767768442965","idStr":"3502767768442965"},"themes":[],"title":"【话题】巴菲特卖苹果,重金出击疫苗股!虎友们,跟不跟?","htmlText":"最近,巴菲特的<a href=\"https://laohu8.com/S/BRK.A\">$伯克希尔(BRK.A)$</a> 做了一些调仓: 卖了3000多万股苹果,不过,其实只是减少了3%,苹果占巴菲特组合的比例仍高达47.78%, 大概有9亿多股[捂脸]; 大幅减持黄金、银行股,其中<a href=\"https://laohu8.com/S/WFC\">$富国银行(WFC)$</a> ,坚持比例高达46%; 重金出击疫苗股,市值接近38亿美元,包含:2130万股<a href=\"https://laohu8.com/S/ABBV\">$艾伯维公司(ABBV)$</a> 、370万股<a href=\"https://laohu8.com/S/PFE\">$辉瑞(PFE)$</a> 、2997万股<a href=\"https://laohu8.com/S/BMY\">$施贵宝(BMY)$</a> 、2240万股<a href=\"https://laohu8.com/S/0O14.UK\">$德国默克(0O14.UK)$</a> 。 值得注意的是,此消息来源根据伯克希尔的最近3季度持仓报告,数据具有明显的延迟性。 另一方面,疫苗股利好消息也不断传出。 近日,另一家美国药企莫德纳<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a> 在11月16日,公布了其新冠疫苗III期实验报告,有效率高达94.5%。 随着新冠疫苗研发竞赛的进行,根据世界卫生组织的统计: 目前有12个新冠候选疫苗已经进入III期阶段,且有效性、安全性都比较明朗,到今年年底或明年年初,疫苗即有可能获得FDA或者欧盟批准上市。 .. ... 最后,大家聊一聊: 虎友们,是否打算跟随股神一起出击医药股? 这次股神会在医药股上,大赚特赚吗? 精彩留言","listText":"最近,巴菲特的<a href=\"https://laohu8.com/S/BRK.A\">$伯克希尔(BRK.A)$</a> 做了一些调仓: 卖了3000多万股苹果,不过,其实只是减少了3%,苹果占巴菲特组合的比例仍高达47.78%, 大概有9亿多股[捂脸]; 大幅减持黄金、银行股,其中<a href=\"https://laohu8.com/S/WFC\">$富国银行(WFC)$</a> ,坚持比例高达46%; 重金出击疫苗股,市值接近38亿美元,包含:2130万股<a href=\"https://laohu8.com/S/ABBV\">$艾伯维公司(ABBV)$</a> 、370万股<a href=\"https://laohu8.com/S/PFE\">$辉瑞(PFE)$</a> 、2997万股<a href=\"https://laohu8.com/S/BMY\">$施贵宝(BMY)$</a> 、2240万股<a href=\"https://laohu8.com/S/0O14.UK\">$德国默克(0O14.UK)$</a> 。 值得注意的是,此消息来源根据伯克希尔的最近3季度持仓报告,数据具有明显的延迟性。 另一方面,疫苗股利好消息也不断传出。 近日,另一家美国药企莫德纳<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a> 在11月16日,公布了其新冠疫苗III期实验报告,有效率高达94.5%。 随着新冠疫苗研发竞赛的进行,根据世界卫生组织的统计: 目前有12个新冠候选疫苗已经进入III期阶段,且有效性、安全性都比较明朗,到今年年底或明年年初,疫苗即有可能获得FDA或者欧盟批准上市。 .. ... 最后,大家聊一聊: 虎友们,是否打算跟随股神一起出击医药股? 这次股神会在医药股上,大赚特赚吗? 精彩留言","text":"最近,巴菲特的$伯克希尔(BRK.A)$ 做了一些调仓: 卖了3000多万股苹果,不过,其实只是减少了3%,苹果占巴菲特组合的比例仍高达47.78%, 大概有9亿多股[捂脸]; 大幅减持黄金、银行股,其中$富国银行(WFC)$ ,坚持比例高达46%; 重金出击疫苗股,市值接近38亿美元,包含:2130万股$艾伯维公司(ABBV)$ 、370万股$辉瑞(PFE)$ 、2997万股$施贵宝(BMY)$ 、2240万股$德国默克(0O14.UK)$ 。 值得注意的是,此消息来源根据伯克希尔的最近3季度持仓报告,数据具有明显的延迟性。 另一方面,疫苗股利好消息也不断传出。 近日,另一家美国药企莫德纳$Moderna, Inc.(MRNA)$ 在11月16日,公布了其新冠疫苗III期实验报告,有效率高达94.5%。 随着新冠疫苗研发竞赛的进行,根据世界卫生组织的统计: 目前有12个新冠候选疫苗已经进入III期阶段,且有效性、安全性都比较明朗,到今年年底或明年年初,疫苗即有可能获得FDA或者欧盟批准上市。 .. ... 最后,大家聊一聊: 虎友们,是否打算跟随股神一起出击医药股? 这次股神会在医药股上,大赚特赚吗? 精彩留言","images":[],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/390064684","isVote":2,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"vote":{"id":1185,"gmtBegin":1605672904820,"gmtEnd":1606018483547,"type":1,"upper":1,"title":"你是否看好医药/疫苗股?","choices":[{"id":4450,"sort":1,"name":"看好,相信股神的眼光!","userSize":187,"voted":false},{"id":4451,"sort":2,"name":"不看好,时机未到!","userSize":57,"voted":false}]},"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1043,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":391100648,"gmtCreate":1606491658384,"gmtModify":1703843422017,"author":{"id":"3568479083861646","authorId":"3568479083861646","name":"titeufakina","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3568479083861646","idStr":"3568479083861646"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/391100648","repostId":"393409223","repostType":1,"repost":{"id":393409223,"gmtCreate":1606343198062,"gmtModify":1703842726548,"author":{"id":"3492424522656615","authorId":"3492424522656615","name":"七仙子","avatar":"https://static.tigerbbs.com/d372870c34ac4cef56b581f38aece2e1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3492424522656615","idStr":"3492424522656615"},"themes":[],"title":"7天翻了一倍多,我是如何抓住这只黑马的?","htmlText":"<a href=\"https://laohu8.com/S/JMIA\">$Jumia Technologies AG(JMIA)$</a>本人关注Jumia这只股票很久了。去年Jumia刚上市我就开始关注了,并且在上市后第一波行情中赚了一笔。但是没过多久Jumia就遭遇香橼做空,加上几次财报数据都很难看,所以股价一泻千里,一路暴跌加阴跌,股价从上市初最高点49.77美元一路跌到最低点2.15美元才开始企稳反弹,这期间的累计跌幅高达95%以上!这段时间我先是多头头寸亏损很大,好在后来承认错误平仓止损并且转为做空,才大幅收复损失。在Jumia股价触及2.15美元低点以后就开始了企稳反弹之路,我这时又转为做多。最近一次财报大跌时我清仓了多头头寸,改为空仓观望,因为我觉得可能还会持续阴跌一段时间才会再次起飞。但我并没有反手做空,因为我觉得Jumia的基本面即将迎来困境反转,此时做空风险无限大,即使短线看空也不能实盘做空。事实证明我没有贸然做空的决策是正确的。因为大多数人预期的阴跌并没有到来,反而股价连续暴涨。我一看不对劲,实际走势和大多数人的预期完全是反着来,于是我不再空仓等待,在财报大跌后连续大涨三天时果断介入,满仓做多。到现在为止已经翻了一倍多,因为我是满仓做多,所以我的美股账户总资产也跟着翻了一倍多。如果我是轻仓参与,虽然股价翻倍,但是我的美股账户总资产也不可能翻倍,这就是我下面要强调的关键时刻要敢于重仓做多的原因。因为对自己的选股有足够的信心,所以才敢满仓做多。我是打算持有几年以上的,即使短期跌了也无所谓。并不是所有的重仓或者满仓都是赌博。轻仓者永远聪明但是永远错过,只有敢于重仓者才能吃到大肉!是否敢于重仓,关键在选股能力。说到选股,不同的人有不同的观点。有的人喜欢价值投资中的基本面选股,有的人喜欢趋势投资中的技术面选股。不能简单说孰优孰劣,本姑娘觉得各有千秋吧,这两种选股","listText":"<a href=\"https://laohu8.com/S/JMIA\">$Jumia Technologies AG(JMIA)$</a>本人关注Jumia这只股票很久了。去年Jumia刚上市我就开始关注了,并且在上市后第一波行情中赚了一笔。但是没过多久Jumia就遭遇香橼做空,加上几次财报数据都很难看,所以股价一泻千里,一路暴跌加阴跌,股价从上市初最高点49.77美元一路跌到最低点2.15美元才开始企稳反弹,这期间的累计跌幅高达95%以上!这段时间我先是多头头寸亏损很大,好在后来承认错误平仓止损并且转为做空,才大幅收复损失。在Jumia股价触及2.15美元低点以后就开始了企稳反弹之路,我这时又转为做多。最近一次财报大跌时我清仓了多头头寸,改为空仓观望,因为我觉得可能还会持续阴跌一段时间才会再次起飞。但我并没有反手做空,因为我觉得Jumia的基本面即将迎来困境反转,此时做空风险无限大,即使短线看空也不能实盘做空。事实证明我没有贸然做空的决策是正确的。因为大多数人预期的阴跌并没有到来,反而股价连续暴涨。我一看不对劲,实际走势和大多数人的预期完全是反着来,于是我不再空仓等待,在财报大跌后连续大涨三天时果断介入,满仓做多。到现在为止已经翻了一倍多,因为我是满仓做多,所以我的美股账户总资产也跟着翻了一倍多。如果我是轻仓参与,虽然股价翻倍,但是我的美股账户总资产也不可能翻倍,这就是我下面要强调的关键时刻要敢于重仓做多的原因。因为对自己的选股有足够的信心,所以才敢满仓做多。我是打算持有几年以上的,即使短期跌了也无所谓。并不是所有的重仓或者满仓都是赌博。轻仓者永远聪明但是永远错过,只有敢于重仓者才能吃到大肉!是否敢于重仓,关键在选股能力。说到选股,不同的人有不同的观点。有的人喜欢价值投资中的基本面选股,有的人喜欢趋势投资中的技术面选股。不能简单说孰优孰劣,本姑娘觉得各有千秋吧,这两种选股","text":"$Jumia Technologies AG(JMIA)$本人关注Jumia这只股票很久了。去年Jumia刚上市我就开始关注了,并且在上市后第一波行情中赚了一笔。但是没过多久Jumia就遭遇香橼做空,加上几次财报数据都很难看,所以股价一泻千里,一路暴跌加阴跌,股价从上市初最高点49.77美元一路跌到最低点2.15美元才开始企稳反弹,这期间的累计跌幅高达95%以上!这段时间我先是多头头寸亏损很大,好在后来承认错误平仓止损并且转为做空,才大幅收复损失。在Jumia股价触及2.15美元低点以后就开始了企稳反弹之路,我这时又转为做多。最近一次财报大跌时我清仓了多头头寸,改为空仓观望,因为我觉得可能还会持续阴跌一段时间才会再次起飞。但我并没有反手做空,因为我觉得Jumia的基本面即将迎来困境反转,此时做空风险无限大,即使短线看空也不能实盘做空。事实证明我没有贸然做空的决策是正确的。因为大多数人预期的阴跌并没有到来,反而股价连续暴涨。我一看不对劲,实际走势和大多数人的预期完全是反着来,于是我不再空仓等待,在财报大跌后连续大涨三天时果断介入,满仓做多。到现在为止已经翻了一倍多,因为我是满仓做多,所以我的美股账户总资产也跟着翻了一倍多。如果我是轻仓参与,虽然股价翻倍,但是我的美股账户总资产也不可能翻倍,这就是我下面要强调的关键时刻要敢于重仓做多的原因。因为对自己的选股有足够的信心,所以才敢满仓做多。我是打算持有几年以上的,即使短期跌了也无所谓。并不是所有的重仓或者满仓都是赌博。轻仓者永远聪明但是永远错过,只有敢于重仓者才能吃到大肉!是否敢于重仓,关键在选股能力。说到选股,不同的人有不同的观点。有的人喜欢价值投资中的基本面选股,有的人喜欢趋势投资中的技术面选股。不能简单说孰优孰劣,本姑娘觉得各有千秋吧,这两种选股","images":[{"img":"https://static.tigerbbs.com/7241138eb18336a2847d6dc07ac8406f","width":"750","height":"1249"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/393409223","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":911,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":391377957,"gmtCreate":1606491531679,"gmtModify":1703843420106,"author":{"id":"3568479083861646","authorId":"3568479083861646","name":"titeufakina","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3568479083861646","idStr":"3568479083861646"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/391377957","repostId":"390064684","repostType":1,"repost":{"id":390064684,"gmtCreate":1605672840142,"gmtModify":1703838916404,"author":{"id":"3502767768442965","authorId":"3502767768442965","name":"话题虎","avatar":"https://static.tigerbbs.com/d418c2def5dc1d094b03270b450f71ce","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3502767768442965","idStr":"3502767768442965"},"themes":[],"title":"【话题】巴菲特卖苹果,重金出击疫苗股!虎友们,跟不跟?","htmlText":"最近,巴菲特的<a href=\"https://laohu8.com/S/BRK.A\">$伯克希尔(BRK.A)$</a> 做了一些调仓: 卖了3000多万股苹果,不过,其实只是减少了3%,苹果占巴菲特组合的比例仍高达47.78%, 大概有9亿多股[捂脸]; 大幅减持黄金、银行股,其中<a href=\"https://laohu8.com/S/WFC\">$富国银行(WFC)$</a> ,坚持比例高达46%; 重金出击疫苗股,市值接近38亿美元,包含:2130万股<a href=\"https://laohu8.com/S/ABBV\">$艾伯维公司(ABBV)$</a> 、370万股<a href=\"https://laohu8.com/S/PFE\">$辉瑞(PFE)$</a> 、2997万股<a href=\"https://laohu8.com/S/BMY\">$施贵宝(BMY)$</a> 、2240万股<a href=\"https://laohu8.com/S/0O14.UK\">$德国默克(0O14.UK)$</a> 。 值得注意的是,此消息来源根据伯克希尔的最近3季度持仓报告,数据具有明显的延迟性。 另一方面,疫苗股利好消息也不断传出。 近日,另一家美国药企莫德纳<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a> 在11月16日,公布了其新冠疫苗III期实验报告,有效率高达94.5%。 随着新冠疫苗研发竞赛的进行,根据世界卫生组织的统计: 目前有12个新冠候选疫苗已经进入III期阶段,且有效性、安全性都比较明朗,到今年年底或明年年初,疫苗即有可能获得FDA或者欧盟批准上市。 .. ... 最后,大家聊一聊: 虎友们,是否打算跟随股神一起出击医药股? 这次股神会在医药股上,大赚特赚吗? 精彩留言","listText":"最近,巴菲特的<a href=\"https://laohu8.com/S/BRK.A\">$伯克希尔(BRK.A)$</a> 做了一些调仓: 卖了3000多万股苹果,不过,其实只是减少了3%,苹果占巴菲特组合的比例仍高达47.78%, 大概有9亿多股[捂脸]; 大幅减持黄金、银行股,其中<a href=\"https://laohu8.com/S/WFC\">$富国银行(WFC)$</a> ,坚持比例高达46%; 重金出击疫苗股,市值接近38亿美元,包含:2130万股<a href=\"https://laohu8.com/S/ABBV\">$艾伯维公司(ABBV)$</a> 、370万股<a href=\"https://laohu8.com/S/PFE\">$辉瑞(PFE)$</a> 、2997万股<a href=\"https://laohu8.com/S/BMY\">$施贵宝(BMY)$</a> 、2240万股<a href=\"https://laohu8.com/S/0O14.UK\">$德国默克(0O14.UK)$</a> 。 值得注意的是,此消息来源根据伯克希尔的最近3季度持仓报告,数据具有明显的延迟性。 另一方面,疫苗股利好消息也不断传出。 近日,另一家美国药企莫德纳<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a> 在11月16日,公布了其新冠疫苗III期实验报告,有效率高达94.5%。 随着新冠疫苗研发竞赛的进行,根据世界卫生组织的统计: 目前有12个新冠候选疫苗已经进入III期阶段,且有效性、安全性都比较明朗,到今年年底或明年年初,疫苗即有可能获得FDA或者欧盟批准上市。 .. ... 最后,大家聊一聊: 虎友们,是否打算跟随股神一起出击医药股? 这次股神会在医药股上,大赚特赚吗? 精彩留言","text":"最近,巴菲特的$伯克希尔(BRK.A)$ 做了一些调仓: 卖了3000多万股苹果,不过,其实只是减少了3%,苹果占巴菲特组合的比例仍高达47.78%, 大概有9亿多股[捂脸]; 大幅减持黄金、银行股,其中$富国银行(WFC)$ ,坚持比例高达46%; 重金出击疫苗股,市值接近38亿美元,包含:2130万股$艾伯维公司(ABBV)$ 、370万股$辉瑞(PFE)$ 、2997万股$施贵宝(BMY)$ 、2240万股$德国默克(0O14.UK)$ 。 值得注意的是,此消息来源根据伯克希尔的最近3季度持仓报告,数据具有明显的延迟性。 另一方面,疫苗股利好消息也不断传出。 近日,另一家美国药企莫德纳$Moderna, Inc.(MRNA)$ 在11月16日,公布了其新冠疫苗III期实验报告,有效率高达94.5%。 随着新冠疫苗研发竞赛的进行,根据世界卫生组织的统计: 目前有12个新冠候选疫苗已经进入III期阶段,且有效性、安全性都比较明朗,到今年年底或明年年初,疫苗即有可能获得FDA或者欧盟批准上市。 .. ... 最后,大家聊一聊: 虎友们,是否打算跟随股神一起出击医药股? 这次股神会在医药股上,大赚特赚吗? 精彩留言","images":[],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/390064684","isVote":2,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"vote":{"id":1185,"gmtBegin":1605672904820,"gmtEnd":1606018483547,"type":1,"upper":1,"title":"你是否看好医药/疫苗股?","choices":[{"id":4450,"sort":1,"name":"看好,相信股神的眼光!","userSize":187,"voted":false},{"id":4451,"sort":2,"name":"不看好,时机未到!","userSize":57,"voted":false}]},"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":774,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":391378275,"gmtCreate":1606491254397,"gmtModify":1703843414027,"author":{"id":"3568479083861646","authorId":"3568479083861646","name":"titeufakina","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3568479083861646","idStr":"3568479083861646"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/391378275","repostId":"390450978","repostType":1,"repost":{"id":390450978,"gmtCreate":1605843648994,"gmtModify":1710940121819,"author":{"id":"3528966054893519","authorId":"3528966054893519","name":"小虎说英股","avatar":"https://static.tigerbbs.com/b444754ad4cb8cbfaf0dcb4fb2537c79","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3528966054893519","idStr":"3528966054893519"},"themes":[],"title":"Regal Cinemas Owner in Talks for Rescue Package","htmlText":"This article is from The Wall Street Journal on November 20th, 2020. 小虎说英股 loves The Wall Street Journal[爱你] <a target=\"_blank\" href=\"https://laohu8.com/S/CINE.UK\">$CINEWORLD(CINE.UK)$</a>is negotiating with lenders as it confronts the threat to its business caused by the pandemicRegal Entertainment Group owner Cineworld Group PLC is in talks with investors for financial lifelines after months of empty theaters in the U.S. and U.K. during the coronavirus pandemic, according to people familiar with the matter.One proposal under consideration would supply rescue financing to help Cineworld avoid filing for protection from creditors, some of the people said.Under an alternate proposal, investors would provide a loan to finance an insolvency proceeding, the British equivalent of bankruptc","listText":"This article is from The Wall Street Journal on November 20th, 2020. 小虎说英股 loves The Wall Street Journal[爱你] <a target=\"_blank\" href=\"https://laohu8.com/S/CINE.UK\">$CINEWORLD(CINE.UK)$</a>is negotiating with lenders as it confronts the threat to its business caused by the pandemicRegal Entertainment Group owner Cineworld Group PLC is in talks with investors for financial lifelines after months of empty theaters in the U.S. and U.K. during the coronavirus pandemic, according to people familiar with the matter.One proposal under consideration would supply rescue financing to help Cineworld avoid filing for protection from creditors, some of the people said.Under an alternate proposal, investors would provide a loan to finance an insolvency proceeding, the British equivalent of bankruptc","text":"This article is from The Wall Street Journal on November 20th, 2020. 小虎说英股 loves The Wall Street Journal[爱你] $CINEWORLD(CINE.UK)$is negotiating with lenders as it confronts the threat to its business caused by the pandemicRegal Entertainment Group owner Cineworld Group PLC is in talks with investors for financial lifelines after months of empty theaters in the U.S. and U.K. during the coronavirus pandemic, according to people familiar with the matter.One proposal under consideration would supply rescue financing to help Cineworld avoid filing for protection from creditors, some of the people said.Under an alternate proposal, investors would provide a loan to finance an insolvency proceeding, the British equivalent of bankruptc","images":[{"img":"https://static.tigerbbs.com/10f8170b4855bcb853ec86f587dd12ff"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/390450978","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":393,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":393578747,"gmtCreate":1606339323589,"gmtModify":1703842718797,"author":{"id":"3568479083861646","authorId":"3568479083861646","name":"titeufakina","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3568479083861646","idStr":"3568479083861646"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/393578747","repostId":"399737732","repostType":1,"repost":{"id":399737732,"gmtCreate":1606188814726,"gmtModify":1703841508657,"author":{"id":"3568564821331838","authorId":"3568564821331838","name":"牧财鲸_踩不到热点版","avatar":"https://static.tigerbbs.com/0696d009cfc0d2b729160bd74e366dd8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3568564821331838","idStr":"3568564821331838"},"themes":[],"title":"分享7个我最常用的美股研究网站。包括筛选器,财报,期权,ETF,IPO,做空,应有尽有。而且免注册!","htmlText":"分享7个我最常用的美股研究网站。包括筛选器,财报,期权,ETF,IPO,做空,应有尽有。而且免费且不需要注册!-01- finviz美股筛选神器。你想要的基本面,技术面,信息面,基本上都会有,而且选项非常全。设置好筛选器后,你还可以根据需要调节成全图表观看,或者全基本面观看,或者多种模式结合。甚至你还可以看到大股东内部仓位变动。-02- barchart这个网站你可以同时查看股票,ETF,期权,期货和外汇。并且不仅能查看美国市场,还能查看加拿大,英国,澳大利亚等国家的市场。我一般会利用这个网站来查看股指期货和高波动率(High Implied Volatility)的期权,从而寻找一些个股的机会。比如你可以点击期权(options),然后左侧选择最活跃期权。接着列表就会按照活跃程度列出个股,同时还会有puts和calls的持仓比例。非常好用。-03- tradingview免费看图表和作图表的网站。你作的图可以储存分享或下载。技术图表爱好者的天堂。同时他还有讨论社区,可以看别人的作图和分析。-04- earningswhispers提前查看知晓公司发布财报的日期和时间。选择日历选项,还可以以日期将公司排序为你呈现。并且还有分析师预测数据,未来指引等数据。-05- money.usnews/funds/etfs了解和筛选美国市场上各种的ETF。包括中国科技ETF,中国互联网ETF等等。上面涵盖关于ETF的所有信息。包括介绍,排名,持仓等等。-06- iposcoop查看近年来在美股市场上市的所有IPO和即将上市的IPO。时间间隔和区间可以任由你的选择。-07- shortsqueeze查看个股被卖空的比例和股数。方便我对个股技术面研究和买入点卖出点的判断。但是这里要提一下,这个网站信息更新比较迟缓。所以卖空数据可能不准确。但目前我又没找到更好的查看这方面数据的网站,所以将就用","listText":"分享7个我最常用的美股研究网站。包括筛选器,财报,期权,ETF,IPO,做空,应有尽有。而且免费且不需要注册!-01- finviz美股筛选神器。你想要的基本面,技术面,信息面,基本上都会有,而且选项非常全。设置好筛选器后,你还可以根据需要调节成全图表观看,或者全基本面观看,或者多种模式结合。甚至你还可以看到大股东内部仓位变动。-02- barchart这个网站你可以同时查看股票,ETF,期权,期货和外汇。并且不仅能查看美国市场,还能查看加拿大,英国,澳大利亚等国家的市场。我一般会利用这个网站来查看股指期货和高波动率(High Implied Volatility)的期权,从而寻找一些个股的机会。比如你可以点击期权(options),然后左侧选择最活跃期权。接着列表就会按照活跃程度列出个股,同时还会有puts和calls的持仓比例。非常好用。-03- tradingview免费看图表和作图表的网站。你作的图可以储存分享或下载。技术图表爱好者的天堂。同时他还有讨论社区,可以看别人的作图和分析。-04- earningswhispers提前查看知晓公司发布财报的日期和时间。选择日历选项,还可以以日期将公司排序为你呈现。并且还有分析师预测数据,未来指引等数据。-05- money.usnews/funds/etfs了解和筛选美国市场上各种的ETF。包括中国科技ETF,中国互联网ETF等等。上面涵盖关于ETF的所有信息。包括介绍,排名,持仓等等。-06- iposcoop查看近年来在美股市场上市的所有IPO和即将上市的IPO。时间间隔和区间可以任由你的选择。-07- shortsqueeze查看个股被卖空的比例和股数。方便我对个股技术面研究和买入点卖出点的判断。但是这里要提一下,这个网站信息更新比较迟缓。所以卖空数据可能不准确。但目前我又没找到更好的查看这方面数据的网站,所以将就用","text":"分享7个我最常用的美股研究网站。包括筛选器,财报,期权,ETF,IPO,做空,应有尽有。而且免费且不需要注册!-01- finviz美股筛选神器。你想要的基本面,技术面,信息面,基本上都会有,而且选项非常全。设置好筛选器后,你还可以根据需要调节成全图表观看,或者全基本面观看,或者多种模式结合。甚至你还可以看到大股东内部仓位变动。-02- barchart这个网站你可以同时查看股票,ETF,期权,期货和外汇。并且不仅能查看美国市场,还能查看加拿大,英国,澳大利亚等国家的市场。我一般会利用这个网站来查看股指期货和高波动率(High Implied Volatility)的期权,从而寻找一些个股的机会。比如你可以点击期权(options),然后左侧选择最活跃期权。接着列表就会按照活跃程度列出个股,同时还会有puts和calls的持仓比例。非常好用。-03- tradingview免费看图表和作图表的网站。你作的图可以储存分享或下载。技术图表爱好者的天堂。同时他还有讨论社区,可以看别人的作图和分析。-04- earningswhispers提前查看知晓公司发布财报的日期和时间。选择日历选项,还可以以日期将公司排序为你呈现。并且还有分析师预测数据,未来指引等数据。-05- money.usnews/funds/etfs了解和筛选美国市场上各种的ETF。包括中国科技ETF,中国互联网ETF等等。上面涵盖关于ETF的所有信息。包括介绍,排名,持仓等等。-06- iposcoop查看近年来在美股市场上市的所有IPO和即将上市的IPO。时间间隔和区间可以任由你的选择。-07- shortsqueeze查看个股被卖空的比例和股数。方便我对个股技术面研究和买入点卖出点的判断。但是这里要提一下,这个网站信息更新比较迟缓。所以卖空数据可能不准确。但目前我又没找到更好的查看这方面数据的网站,所以将就用","images":[{"img":"https://static.tigerbbs.com/4d65e9165a6ba73bcf857fbbd7509dce","width":"1080","height":"763"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/399737732","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":10,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1229,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":393578645,"gmtCreate":1606338858887,"gmtModify":1703842718109,"author":{"id":"3568479083861646","authorId":"3568479083861646","name":"titeufakina","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3568479083861646","idStr":"3568479083861646"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/393578645","repostId":"393136887","repostType":1,"repost":{"id":393136887,"gmtCreate":1606244724345,"gmtModify":1703842063506,"author":{"id":"3468322318173915","authorId":"3468322318173915","name":"阳光财经","avatar":"https://static.tigerbbs.com/ae4ab676f150a8d357cb5f3e4956d1a0","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3468322318173915","idStr":"3468322318173915"},"themes":[],"title":"","htmlText":"\n \n \n 美股分析2021年风险前瞻:美股估值历史最高位!2021年会不会迎来系统性风险?\n \n","listText":"美股分析2021年风险前瞻:美股估值历史最高位!2021年会不会迎来系统性风险?","text":"美股分析2021年风险前瞻:美股估值历史最高位!2021年会不会迎来系统性风险?","images":[],"top":1,"highlighted":2,"essential":2,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/393136887","isVote":1,"tweetType":2,"object":{"id":"8996d45defe5411e8639ebe4d09a5caf","tweetId":"393136887","title":"美股分析2021年风险前瞻:美股估值历史最高位!2021年会不会迎来系统性风险?","videoUrl":"http://v.tigerbbs.com/160624472122803ce512d367597e8f61108c42c9bc5f9.mp4","poster":"https://static.tigerbbs.com/b63dfa1c3848a5c84866efb48942a9dd","shareLink":"http://v.tigerbbs.com/160624472122803ce512d367597e8f61108c42c9bc5f9.mp4"},"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":611,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":399296197,"gmtCreate":1606137582219,"gmtModify":1703841070763,"author":{"id":"3568479083861646","authorId":"3568479083861646","name":"titeufakina","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3568479083861646","idStr":"3568479083861646"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/399296197","repostId":"390823726","repostType":1,"repost":{"id":390823726,"gmtCreate":1605770401365,"gmtModify":1703839473017,"author":{"id":"3540166583692073","authorId":"3540166583692073","name":"爱投学院","avatar":"https://static.tigerbbs.com/8def4c9b37e078bb8f8421d71f6603d4","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3540166583692073","idStr":"3540166583692073"},"themes":[],"title":"中概股简直涨疯了,这只未来的Youtube,千万别错过!","htmlText":"\n \n \n 大疫情背景下,中概股简直是独领风骚。曾经被大部分人不看好的二次元小破站,如今也崛起成为了多媒体平台帝国了。想知道这是哪只巨大的潜力股吗,点开视频看看吧!<a target=\"_blank\" href=\"https://laohu8.com/S/BILI\">$哔哩哔哩(BILI)$</a> <a target=\"_blank\" href=\"https://laohu8.com/S/GOOG\">$谷歌(GOOG)$</a> <a target=\"_blank\" href=\"https://laohu8.com/S/BABA\">$阿里巴巴(BABA)$</a> 公司于今日发布了未经审计的三季报,营收32.3亿元,同比增长74%,超出预期!本季度,用户日均视频播放量达到创记录的13亿次,同比提升77%。随着社区参与度的持续走高,用户日均使用时长高达81分钟。本季度月均付费用户数同比增长89%达1500万,期待未来的盈利能力不断提升。公司对2020年第四季度收入进行了展望,预计将达到36.0亿元至37.0亿元人民币。爱投学院与老虎联合推出最畅销<a href=\"https://www.laohu8.com/m/space?userId=3540166583692073\" target=\"_blank\">北美投资课程</a>,北美专家手把手教你分析,授之以渔,把财富增值掌握在自己手中。无论美股、港股还是A股,这些经验和方法都非常适用。快来感受原汁原味的北美独立观点,和我们踏上财富自由的旅程。\n \n","listText":"大疫情背景下,中概股简直是独领风骚。曾经被大部分人不看好的二次元小破站,如今也崛起成为了多媒体平台帝国了。想知道这是哪只巨大的潜力股吗,点开视频看看吧!<a target=\"_blank\" href=\"https://laohu8.com/S/BILI\">$哔哩哔哩(BILI)$</a> <a target=\"_blank\" href=\"https://laohu8.com/S/GOOG\">$谷歌(GOOG)$</a> <a target=\"_blank\" href=\"https://laohu8.com/S/BABA\">$阿里巴巴(BABA)$</a> 公司于今日发布了未经审计的三季报,营收32.3亿元,同比增长74%,超出预期!本季度,用户日均视频播放量达到创记录的13亿次,同比提升77%。随着社区参与度的持续走高,用户日均使用时长高达81分钟。本季度月均付费用户数同比增长89%达1500万,期待未来的盈利能力不断提升。公司对2020年第四季度收入进行了展望,预计将达到36.0亿元至37.0亿元人民币。爱投学院与老虎联合推出最畅销<a href=\"https://www.laohu8.com/m/space?userId=3540166583692073\" target=\"_blank\">北美投资课程</a>,北美专家手把手教你分析,授之以渔,把财富增值掌握在自己手中。无论美股、港股还是A股,这些经验和方法都非常适用。快来感受原汁原味的北美独立观点,和我们踏上财富自由的旅程。","text":"大疫情背景下,中概股简直是独领风骚。曾经被大部分人不看好的二次元小破站,如今也崛起成为了多媒体平台帝国了。想知道这是哪只巨大的潜力股吗,点开视频看看吧!$哔哩哔哩(BILI)$ $谷歌(GOOG)$ $阿里巴巴(BABA)$ 公司于今日发布了未经审计的三季报,营收32.3亿元,同比增长74%,超出预期!本季度,用户日均视频播放量达到创记录的13亿次,同比提升77%。随着社区参与度的持续走高,用户日均使用时长高达81分钟。本季度月均付费用户数同比增长89%达1500万,期待未来的盈利能力不断提升。公司对2020年第四季度收入进行了展望,预计将达到36.0亿元至37.0亿元人民币。爱投学院与老虎联合推出最畅销北美投资课程,北美专家手把手教你分析,授之以渔,把财富增值掌握在自己手中。无论美股、港股还是A股,这些经验和方法都非常适用。快来感受原汁原味的北美独立观点,和我们踏上财富自由的旅程。","images":[{"img":"https://static.tigerbbs.com/10de52ca8e448635f4ae456a79adb176","width":"0","height":"0"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/390823726","isVote":1,"tweetType":2,"object":{"id":"c2c850deb4c94b898aa42de7d6a844c1","tweetId":"390823726","videoUrl":"https://1254107296.vod2.myqcloud.com/27e1f7ecvodtransgzp1254107296/9405da815285890810101550774/v.f30.mp4","poster":"https://static.tigerbbs.com/10de52ca8e448635f4ae456a79adb176"},"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1011,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":399207835,"gmtCreate":1606136255327,"gmtModify":1703841061425,"author":{"id":"3568479083861646","authorId":"3568479083861646","name":"titeufakina","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3568479083861646","idStr":"3568479083861646"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/399207835","repostId":"307533803","repostType":1,"repost":{"id":307533803,"gmtCreate":1605589645502,"gmtModify":1703838449425,"author":{"id":"3497328009582754","authorId":"3497328009582754","name":"桃李春风益点财","avatar":"https://static.tigerbbs.com/dc8827e0d2ccb8087a4e15cbe447ad5c","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3497328009582754","idStr":"3497328009582754"},"themes":[],"title":"美国疫苗即将上市,中国暗自发力,谁将成为全球疫情终结者?","htmlText":"\n \n \n 这次疫苗真的要来了。昨夜,Moderna<a target=\"_blank\" href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a> 宣布,他们研发的疫苗有效率高达94.5%。上周,辉瑞<a target=\"_blank\" href=\"https://laohu8.com/S/PFE\">$辉瑞(PFE)$</a> 公司和德国生物技术公司BioNTech<a target=\"_blank\" href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a> 表示,他们的疫苗在预防新冠方面的效果超过90%,比普通流感疫苗70%的有效率足足高出20%!疫苗捷报频传,这是否意味着我们翘首以盼的疫苗即将问世?疫苗分发的时间表出来了吗?其安全性和有效性方面是否让人放心?对于这几个问题,我们采访了The Pinea Group 的 CEO 和首席执行官马蓓女士。\n \n","listText":"这次疫苗真的要来了。昨夜,Moderna<a target=\"_blank\" href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a> 宣布,他们研发的疫苗有效率高达94.5%。上周,辉瑞<a target=\"_blank\" href=\"https://laohu8.com/S/PFE\">$辉瑞(PFE)$</a> 公司和德国生物技术公司BioNTech<a target=\"_blank\" href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a> 表示,他们的疫苗在预防新冠方面的效果超过90%,比普通流感疫苗70%的有效率足足高出20%!疫苗捷报频传,这是否意味着我们翘首以盼的疫苗即将问世?疫苗分发的时间表出来了吗?其安全性和有效性方面是否让人放心?对于这几个问题,我们采访了The Pinea Group 的 CEO 和首席执行官马蓓女士。","text":"这次疫苗真的要来了。昨夜,Moderna$Moderna, Inc.(MRNA)$ 宣布,他们研发的疫苗有效率高达94.5%。上周,辉瑞$辉瑞(PFE)$ 公司和德国生物技术公司BioNTech$BioNTech SE(BNTX)$ 表示,他们的疫苗在预防新冠方面的效果超过90%,比普通流感疫苗70%的有效率足足高出20%!疫苗捷报频传,这是否意味着我们翘首以盼的疫苗即将问世?疫苗分发的时间表出来了吗?其安全性和有效性方面是否让人放心?对于这几个问题,我们采访了The Pinea Group 的 CEO 和首席执行官马蓓女士。","images":[{"img":"https://static.tigerbbs.com/6a10924389eb4ce37186655b93b19a85","width":"0","height":"0"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/307533803","isVote":1,"tweetType":2,"object":{"id":"8679068a5feb40f7896519ca2eb17913","tweetId":"307533803","videoUrl":"https://1254107296.vod2.myqcloud.com/27e1f7ecvodtransgzp1254107296/655bc3755285890809944129364/v.f30.mp4","poster":"https://static.tigerbbs.com/6a10924389eb4ce37186655b93b19a85"},"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1006,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":399204340,"gmtCreate":1606135977780,"gmtModify":1703841059355,"author":{"id":"3568479083861646","authorId":"3568479083861646","name":"titeufakina","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3568479083861646","idStr":"3568479083861646"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/399204340","repostId":"399806024","repostType":1,"repost":{"id":399806024,"gmtCreate":1606071924662,"gmtModify":1703840766606,"author":{"id":"3568528271227724","authorId":"3568528271227724","name":"三藏的财富频道","avatar":"https://static.tigerbbs.com/e56a036257cba67506166ea587b3fbb8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3568528271227724","idStr":"3568528271227724"},"themes":[],"title":"","htmlText":"\n \n \n 与大家一起复盘一下ARK对冲基金的投资报告复盘,抄作业的朋友看过来~大家喜欢三藏的视频不要忘记关注,点赞加评论哦! 感谢大家! $Ark Fintech Innovation ETF(ARKF)$ $Ark Restaurants Corp(ARKR)$ $ARK Web x.0 ETF(ARKW)$\n \n","listText":"与大家一起复盘一下ARK对冲基金的投资报告复盘,抄作业的朋友看过来~大家喜欢三藏的视频不要忘记关注,点赞加评论哦! 感谢大家! $Ark Fintech Innovation ETF(ARKF)$ $Ark Restaurants Corp(ARKR)$ $ARK Web x.0 ETF(ARKW)$","text":"与大家一起复盘一下ARK对冲基金的投资报告复盘,抄作业的朋友看过来~大家喜欢三藏的视频不要忘记关注,点赞加评论哦! 感谢大家! $Ark Fintech Innovation ETF(ARKF)$ $Ark Restaurants Corp(ARKR)$ $ARK Web x.0 ETF(ARKW)$","images":[],"top":1,"highlighted":2,"essential":2,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/399806024","isVote":1,"tweetType":2,"object":{"id":"d600af7974ff469f8843121fd511da15","tweetId":"399806024","title":"ARK行业白皮书 2020 年终回顾!为何如此看好特斯拉? Cathie Wood目光独到,电车行业绝对多头!最值得抄的作业!","videoUrl":"http://v.tigerbbs.com/160607192197495f86d3c6779c8e89a8e42a08939c2f9.mp4","poster":"https://static.tigerbbs.com/405380e6dd722b75b3dc46b8ea4783ee","shareLink":"http://v.tigerbbs.com/160607192197495f86d3c6779c8e89a8e42a08939c2f9.mp4"},"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1074,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":399152216,"gmtCreate":1606044996635,"gmtModify":1703840729215,"author":{"id":"3568479083861646","authorId":"3568479083861646","name":"titeufakina","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3568479083861646","idStr":"3568479083861646"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/399152216","repostId":"307125783","repostType":1,"repost":{"id":307125783,"gmtCreate":1605518907842,"gmtModify":1703837951621,"author":{"id":"3503452965237041","authorId":"3503452965237041","name":"美股研究社","avatar":"https://static.tigerbbs.com/a239c7906133df1f3817d0746a8a0ba1","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3503452965237041","idStr":"3503452965237041"},"themes":[],"title":"股神“偏爱”这三只股,投资者该“抄作业”吗?","htmlText":"作为伯克希尔·哈撒韦公司的首席执行官,沃伦·巴菲特已经养成了不太喜欢科技股的名声,他更喜欢专注于不那么复杂的业务。但巴菲特近年来已开始投资一些科技股,顶级科技投资一直是伯克希尔投资组合中表现最佳的资产之一。考虑到这一点,我们请三位《Motley Fool》撰稿人简要介绍了一些由巴菲特支持、值得马上买进的科技股。继续读下去,看看他们为什么认为StoneCo(STNE)、亚马逊(AMZN)和苹果(AAPL)具备成为赢家的条件。伯克希尔最热门的股票之一<a target=\"_blank\" href=\"https://laohu8.com/S/STNE\">$StoneCo(STNE)$</a> Keith Noonan(StoneCo):在这家巴西金融科技公司两年前首次公开募股时,巴菲特和伯克希尔哈撒韦公司在StoneCo建立了相当大的头寸。该公司股价已较每股24美元的IPO价格上涨了约170%,长期来看,该股仍有诱人的上行空间。与美国、欧洲和亚洲大部分地区相比,巴西支付处理服务的使用率仍然较低,但随着巴西人越来越依赖银行卡和手机支付而不是现金进行日常交易,这一领域仍有很大的增长空间。该公司还有望从巴西和其他拉美国家在线零售的增长中获益。摩根大通2019年的一份报告估计,电子商务仅占巴西整体零售市场的3.2%。电子商务的长期增长将刺激支付处理服务的需求,StoneCo已经看到了这一趋势的好处。尽管冠状病毒导致实体零售店暂时关闭,客流量减少,但该公司仍实现了强劲增长,整体业绩开始改善,门店运营接近正常水平。第三季度,StoneCo成功增加了6.3万名新商户客户,调整后通过该公司平台进行的支付总额同比飙升48%。同期调整后的销售额同比增长46%。该公司应该会继续保持强劲增长,因为它将在其支付平台吸引更多的商家合作伙伴,并从整个平台的交易总额中抽取一小部分。StoneCo的表现","listText":"作为伯克希尔·哈撒韦公司的首席执行官,沃伦·巴菲特已经养成了不太喜欢科技股的名声,他更喜欢专注于不那么复杂的业务。但巴菲特近年来已开始投资一些科技股,顶级科技投资一直是伯克希尔投资组合中表现最佳的资产之一。考虑到这一点,我们请三位《Motley Fool》撰稿人简要介绍了一些由巴菲特支持、值得马上买进的科技股。继续读下去,看看他们为什么认为StoneCo(STNE)、亚马逊(AMZN)和苹果(AAPL)具备成为赢家的条件。伯克希尔最热门的股票之一<a target=\"_blank\" href=\"https://laohu8.com/S/STNE\">$StoneCo(STNE)$</a> Keith Noonan(StoneCo):在这家巴西金融科技公司两年前首次公开募股时,巴菲特和伯克希尔哈撒韦公司在StoneCo建立了相当大的头寸。该公司股价已较每股24美元的IPO价格上涨了约170%,长期来看,该股仍有诱人的上行空间。与美国、欧洲和亚洲大部分地区相比,巴西支付处理服务的使用率仍然较低,但随着巴西人越来越依赖银行卡和手机支付而不是现金进行日常交易,这一领域仍有很大的增长空间。该公司还有望从巴西和其他拉美国家在线零售的增长中获益。摩根大通2019年的一份报告估计,电子商务仅占巴西整体零售市场的3.2%。电子商务的长期增长将刺激支付处理服务的需求,StoneCo已经看到了这一趋势的好处。尽管冠状病毒导致实体零售店暂时关闭,客流量减少,但该公司仍实现了强劲增长,整体业绩开始改善,门店运营接近正常水平。第三季度,StoneCo成功增加了6.3万名新商户客户,调整后通过该公司平台进行的支付总额同比飙升48%。同期调整后的销售额同比增长46%。该公司应该会继续保持强劲增长,因为它将在其支付平台吸引更多的商家合作伙伴,并从整个平台的交易总额中抽取一小部分。StoneCo的表现","text":"作为伯克希尔·哈撒韦公司的首席执行官,沃伦·巴菲特已经养成了不太喜欢科技股的名声,他更喜欢专注于不那么复杂的业务。但巴菲特近年来已开始投资一些科技股,顶级科技投资一直是伯克希尔投资组合中表现最佳的资产之一。考虑到这一点,我们请三位《Motley Fool》撰稿人简要介绍了一些由巴菲特支持、值得马上买进的科技股。继续读下去,看看他们为什么认为StoneCo(STNE)、亚马逊(AMZN)和苹果(AAPL)具备成为赢家的条件。伯克希尔最热门的股票之一$StoneCo(STNE)$ Keith Noonan(StoneCo):在这家巴西金融科技公司两年前首次公开募股时,巴菲特和伯克希尔哈撒韦公司在StoneCo建立了相当大的头寸。该公司股价已较每股24美元的IPO价格上涨了约170%,长期来看,该股仍有诱人的上行空间。与美国、欧洲和亚洲大部分地区相比,巴西支付处理服务的使用率仍然较低,但随着巴西人越来越依赖银行卡和手机支付而不是现金进行日常交易,这一领域仍有很大的增长空间。该公司还有望从巴西和其他拉美国家在线零售的增长中获益。摩根大通2019年的一份报告估计,电子商务仅占巴西整体零售市场的3.2%。电子商务的长期增长将刺激支付处理服务的需求,StoneCo已经看到了这一趋势的好处。尽管冠状病毒导致实体零售店暂时关闭,客流量减少,但该公司仍实现了强劲增长,整体业绩开始改善,门店运营接近正常水平。第三季度,StoneCo成功增加了6.3万名新商户客户,调整后通过该公司平台进行的支付总额同比飙升48%。同期调整后的销售额同比增长46%。该公司应该会继续保持强劲增长,因为它将在其支付平台吸引更多的商家合作伙伴,并从整个平台的交易总额中抽取一小部分。StoneCo的表现","images":[{"img":"https://static.tigerbbs.com/e5b01d0286933483e1f024d482ed201e","width":"640","height":"360"}],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/307125783","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":983,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":399152806,"gmtCreate":1606044855605,"gmtModify":1703840729042,"author":{"id":"3568479083861646","authorId":"3568479083861646","name":"titeufakina","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3568479083861646","idStr":"3568479083861646"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/399152806","repostId":"2084281420","repostType":4,"repost":{"id":"2084281420","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1062363208","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1605860434,"share":"https://www.laohu8.com/m/news/2084281420?lang=&edition=full","pubTime":"2020-11-20 16:20","market":"other","language":"en","title":"Novartis signs $50 mln deal for Mesoblast cell therapy for COVID, beyond","url":"https://stock-news.laohu8.com/highlight/detail?id=2084281420","media":"Reuters","summary":"ZURICH, Nov 20 (Reuters) - Novartis aims to boost its respiratory treatment portfolio with a $50 mil","content":"<p>ZURICH, Nov 20 (Reuters) - Novartis aims to boost its respiratory treatment portfolio with a $50 million deal for an off-the-shelf cell therapy from Mesoblast that it hopes to deploy for COVID-19 patients as well as others suffering from respiratory distress.</p><p>The Swiss drugmaker's deal with Australia-based Mesoblast secures rights to develop, commercialize and manufacture Remestemcel-L for treating acute respiratory distress syndrome <a href=\"https://laohu8.com/S/ARDS\">$(ARDS)$</a>, including that associated with COVID-19, for which the therapy is currently in late-stage trials.</p><p>While the therapy has shown promise in COVID-19 patients -- -- in a compassionate use programme in March in 12 patients, Remestemcel-L was associated with an 83% survival rate -- Novartis wants the medicine for beyond the pandemic, too, to help patients who in normal times also land in the hospital with ARDS and often die.</p><p>\"It has the potential to be the first treatment for the most critically ill ARDS patients, and it provides us with an opportunity to apply years of specialized experience directly to the work of saving lives,\" Novartis's chief drug developer, John Tsai, said on Friday.</p><p>Unlike Kymriah, Novartis's cancer cell therapy, Remestemcel-L does not have to be tailored for each patient. Once the deal is closed, Novartis said it is planning to help Mesoblast work on quality attributes of the therapy so it meets U.S. Food and Drug Administration requirements necessary for late-stage trial beyond COVID-19.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis signs $50 mln deal for Mesoblast cell therapy for COVID, beyond</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis signs $50 mln deal for Mesoblast cell therapy for COVID, beyond\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1062363208\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2020-11-20 16:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ZURICH, Nov 20 (Reuters) - Novartis aims to boost its respiratory treatment portfolio with a $50 million deal for an off-the-shelf cell therapy from Mesoblast that it hopes to deploy for COVID-19 patients as well as others suffering from respiratory distress.</p><p>The Swiss drugmaker's deal with Australia-based Mesoblast secures rights to develop, commercialize and manufacture Remestemcel-L for treating acute respiratory distress syndrome <a href=\"https://laohu8.com/S/ARDS\">$(ARDS)$</a>, including that associated with COVID-19, for which the therapy is currently in late-stage trials.</p><p>While the therapy has shown promise in COVID-19 patients -- -- in a compassionate use programme in March in 12 patients, Remestemcel-L was associated with an 83% survival rate -- Novartis wants the medicine for beyond the pandemic, too, to help patients who in normal times also land in the hospital with ARDS and often die.</p><p>\"It has the potential to be the first treatment for the most critically ill ARDS patients, and it provides us with an opportunity to apply years of specialized experience directly to the work of saving lives,\" Novartis's chief drug developer, John Tsai, said on Friday.</p><p>Unlike Kymriah, Novartis's cancer cell therapy, Remestemcel-L does not have to be tailored for each patient. Once the deal is closed, Novartis said it is planning to help Mesoblast work on quality attributes of the therapy so it meets U.S. Food and Drug Administration requirements necessary for late-stage trial beyond COVID-19.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MSB.AU":"MESOBLAST LTD","NVS":"诺华"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2084281420","content_text":"ZURICH, Nov 20 (Reuters) - Novartis aims to boost its respiratory treatment portfolio with a $50 million deal for an off-the-shelf cell therapy from Mesoblast that it hopes to deploy for COVID-19 patients as well as others suffering from respiratory distress.The Swiss drugmaker's deal with Australia-based Mesoblast secures rights to develop, commercialize and manufacture Remestemcel-L for treating acute respiratory distress syndrome $(ARDS)$, including that associated with COVID-19, for which the therapy is currently in late-stage trials.While the therapy has shown promise in COVID-19 patients -- -- in a compassionate use programme in March in 12 patients, Remestemcel-L was associated with an 83% survival rate -- Novartis wants the medicine for beyond the pandemic, too, to help patients who in normal times also land in the hospital with ARDS and often die.\"It has the potential to be the first treatment for the most critically ill ARDS patients, and it provides us with an opportunity to apply years of specialized experience directly to the work of saving lives,\" Novartis's chief drug developer, John Tsai, said on Friday.Unlike Kymriah, Novartis's cancer cell therapy, Remestemcel-L does not have to be tailored for each patient. Once the deal is closed, Novartis said it is planning to help Mesoblast work on quality attributes of the therapy so it meets U.S. Food and Drug Administration requirements necessary for late-stage trial beyond COVID-19.","news_type":1},"isVote":1,"tweetType":1,"viewCount":602,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":399101595,"gmtCreate":1605987183417,"gmtModify":1703840628910,"author":{"id":"3568479083861646","authorId":"3568479083861646","name":"titeufakina","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3568479083861646","idStr":"3568479083861646"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/399101595","repostId":"2084287883","repostType":4,"isVote":1,"tweetType":1,"viewCount":1050,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3527667803686145","authorId":"3527667803686145","name":"社区成长助手","avatar":"https://static.tigerbbs.com/2b7c7106b5c0c8b0037faa67439d898f","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3527667803686145","idStr":"3527667803686145"},"content":"终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题,可以获得更多曝光哦~如果您想创作优质文章,请查看老虎社区创作指引","text":"终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题,可以获得更多曝光哦~如果您想创作优质文章,请查看老虎社区创作指引","html":"终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题,可以获得更多曝光哦~如果您想创作优质文章,请查看老虎社区创作指引"}],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":399101595,"gmtCreate":1605987183417,"gmtModify":1703840628910,"author":{"id":"3568479083861646","authorId":"3568479083861646","name":"titeufakina","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568479083861646","authorIdStr":"3568479083861646"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/399101595","repostId":"2084287883","repostType":4,"isVote":1,"tweetType":1,"viewCount":1050,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3527667803686145","authorId":"3527667803686145","name":"社区成长助手","avatar":"https://static.tigerbbs.com/2b7c7106b5c0c8b0037faa67439d898f","crmLevel":1,"crmLevelSwitch":0,"idStr":"3527667803686145","authorIdStr":"3527667803686145"},"content":"终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题,可以获得更多曝光哦~如果您想创作优质文章,请查看老虎社区创作指引","text":"终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题,可以获得更多曝光哦~如果您想创作优质文章,请查看老虎社区创作指引","html":"终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题,可以获得更多曝光哦~如果您想创作优质文章,请查看老虎社区创作指引"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":391879094,"gmtCreate":1606599136318,"gmtModify":1703843685505,"author":{"id":"3568479083861646","authorId":"3568479083861646","name":"titeufakina","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568479083861646","authorIdStr":"3568479083861646"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/391879094","repostId":"390064684","repostType":1,"repost":{"id":390064684,"gmtCreate":1605672840142,"gmtModify":1703838916404,"author":{"id":"3502767768442965","authorId":"3502767768442965","name":"话题虎","avatar":"https://static.tigerbbs.com/d418c2def5dc1d094b03270b450f71ce","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3502767768442965","authorIdStr":"3502767768442965"},"themes":[],"title":"【话题】巴菲特卖苹果,重金出击疫苗股!虎友们,跟不跟?","htmlText":"最近,巴菲特的<a href=\"https://laohu8.com/S/BRK.A\">$伯克希尔(BRK.A)$</a> 做了一些调仓: 卖了3000多万股苹果,不过,其实只是减少了3%,苹果占巴菲特组合的比例仍高达47.78%, 大概有9亿多股[捂脸]; 大幅减持黄金、银行股,其中<a href=\"https://laohu8.com/S/WFC\">$富国银行(WFC)$</a> ,坚持比例高达46%; 重金出击疫苗股,市值接近38亿美元,包含:2130万股<a href=\"https://laohu8.com/S/ABBV\">$艾伯维公司(ABBV)$</a> 、370万股<a href=\"https://laohu8.com/S/PFE\">$辉瑞(PFE)$</a> 、2997万股<a href=\"https://laohu8.com/S/BMY\">$施贵宝(BMY)$</a> 、2240万股<a href=\"https://laohu8.com/S/0O14.UK\">$德国默克(0O14.UK)$</a> 。 值得注意的是,此消息来源根据伯克希尔的最近3季度持仓报告,数据具有明显的延迟性。 另一方面,疫苗股利好消息也不断传出。 近日,另一家美国药企莫德纳<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a> 在11月16日,公布了其新冠疫苗III期实验报告,有效率高达94.5%。 随着新冠疫苗研发竞赛的进行,根据世界卫生组织的统计: 目前有12个新冠候选疫苗已经进入III期阶段,且有效性、安全性都比较明朗,到今年年底或明年年初,疫苗即有可能获得FDA或者欧盟批准上市。 .. ... 最后,大家聊一聊: 虎友们,是否打算跟随股神一起出击医药股? 这次股神会在医药股上,大赚特赚吗? 精彩留言","listText":"最近,巴菲特的<a href=\"https://laohu8.com/S/BRK.A\">$伯克希尔(BRK.A)$</a> 做了一些调仓: 卖了3000多万股苹果,不过,其实只是减少了3%,苹果占巴菲特组合的比例仍高达47.78%, 大概有9亿多股[捂脸]; 大幅减持黄金、银行股,其中<a href=\"https://laohu8.com/S/WFC\">$富国银行(WFC)$</a> ,坚持比例高达46%; 重金出击疫苗股,市值接近38亿美元,包含:2130万股<a href=\"https://laohu8.com/S/ABBV\">$艾伯维公司(ABBV)$</a> 、370万股<a href=\"https://laohu8.com/S/PFE\">$辉瑞(PFE)$</a> 、2997万股<a href=\"https://laohu8.com/S/BMY\">$施贵宝(BMY)$</a> 、2240万股<a href=\"https://laohu8.com/S/0O14.UK\">$德国默克(0O14.UK)$</a> 。 值得注意的是,此消息来源根据伯克希尔的最近3季度持仓报告,数据具有明显的延迟性。 另一方面,疫苗股利好消息也不断传出。 近日,另一家美国药企莫德纳<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a> 在11月16日,公布了其新冠疫苗III期实验报告,有效率高达94.5%。 随着新冠疫苗研发竞赛的进行,根据世界卫生组织的统计: 目前有12个新冠候选疫苗已经进入III期阶段,且有效性、安全性都比较明朗,到今年年底或明年年初,疫苗即有可能获得FDA或者欧盟批准上市。 .. ... 最后,大家聊一聊: 虎友们,是否打算跟随股神一起出击医药股? 这次股神会在医药股上,大赚特赚吗? 精彩留言","text":"最近,巴菲特的$伯克希尔(BRK.A)$ 做了一些调仓: 卖了3000多万股苹果,不过,其实只是减少了3%,苹果占巴菲特组合的比例仍高达47.78%, 大概有9亿多股[捂脸]; 大幅减持黄金、银行股,其中$富国银行(WFC)$ ,坚持比例高达46%; 重金出击疫苗股,市值接近38亿美元,包含:2130万股$艾伯维公司(ABBV)$ 、370万股$辉瑞(PFE)$ 、2997万股$施贵宝(BMY)$ 、2240万股$德国默克(0O14.UK)$ 。 值得注意的是,此消息来源根据伯克希尔的最近3季度持仓报告,数据具有明显的延迟性。 另一方面,疫苗股利好消息也不断传出。 近日,另一家美国药企莫德纳$Moderna, Inc.(MRNA)$ 在11月16日,公布了其新冠疫苗III期实验报告,有效率高达94.5%。 随着新冠疫苗研发竞赛的进行,根据世界卫生组织的统计: 目前有12个新冠候选疫苗已经进入III期阶段,且有效性、安全性都比较明朗,到今年年底或明年年初,疫苗即有可能获得FDA或者欧盟批准上市。 .. ... 最后,大家聊一聊: 虎友们,是否打算跟随股神一起出击医药股? 这次股神会在医药股上,大赚特赚吗? 精彩留言","images":[],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/390064684","isVote":2,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"vote":{"id":1185,"gmtBegin":1605672904820,"gmtEnd":1606018483547,"type":1,"upper":1,"title":"你是否看好医药/疫苗股?","choices":[{"id":4450,"sort":1,"name":"看好,相信股神的眼光!","userSize":187,"voted":false},{"id":4451,"sort":2,"name":"不看好,时机未到!","userSize":57,"voted":false}]},"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1043,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":391100648,"gmtCreate":1606491658384,"gmtModify":1703843422017,"author":{"id":"3568479083861646","authorId":"3568479083861646","name":"titeufakina","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568479083861646","authorIdStr":"3568479083861646"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/391100648","repostId":"393409223","repostType":1,"repost":{"id":393409223,"gmtCreate":1606343198062,"gmtModify":1703842726548,"author":{"id":"3492424522656615","authorId":"3492424522656615","name":"七仙子","avatar":"https://static.tigerbbs.com/d372870c34ac4cef56b581f38aece2e1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3492424522656615","authorIdStr":"3492424522656615"},"themes":[],"title":"7天翻了一倍多,我是如何抓住这只黑马的?","htmlText":"<a href=\"https://laohu8.com/S/JMIA\">$Jumia Technologies AG(JMIA)$</a>本人关注Jumia这只股票很久了。去年Jumia刚上市我就开始关注了,并且在上市后第一波行情中赚了一笔。但是没过多久Jumia就遭遇香橼做空,加上几次财报数据都很难看,所以股价一泻千里,一路暴跌加阴跌,股价从上市初最高点49.77美元一路跌到最低点2.15美元才开始企稳反弹,这期间的累计跌幅高达95%以上!这段时间我先是多头头寸亏损很大,好在后来承认错误平仓止损并且转为做空,才大幅收复损失。在Jumia股价触及2.15美元低点以后就开始了企稳反弹之路,我这时又转为做多。最近一次财报大跌时我清仓了多头头寸,改为空仓观望,因为我觉得可能还会持续阴跌一段时间才会再次起飞。但我并没有反手做空,因为我觉得Jumia的基本面即将迎来困境反转,此时做空风险无限大,即使短线看空也不能实盘做空。事实证明我没有贸然做空的决策是正确的。因为大多数人预期的阴跌并没有到来,反而股价连续暴涨。我一看不对劲,实际走势和大多数人的预期完全是反着来,于是我不再空仓等待,在财报大跌后连续大涨三天时果断介入,满仓做多。到现在为止已经翻了一倍多,因为我是满仓做多,所以我的美股账户总资产也跟着翻了一倍多。如果我是轻仓参与,虽然股价翻倍,但是我的美股账户总资产也不可能翻倍,这就是我下面要强调的关键时刻要敢于重仓做多的原因。因为对自己的选股有足够的信心,所以才敢满仓做多。我是打算持有几年以上的,即使短期跌了也无所谓。并不是所有的重仓或者满仓都是赌博。轻仓者永远聪明但是永远错过,只有敢于重仓者才能吃到大肉!是否敢于重仓,关键在选股能力。说到选股,不同的人有不同的观点。有的人喜欢价值投资中的基本面选股,有的人喜欢趋势投资中的技术面选股。不能简单说孰优孰劣,本姑娘觉得各有千秋吧,这两种选股","listText":"<a href=\"https://laohu8.com/S/JMIA\">$Jumia Technologies AG(JMIA)$</a>本人关注Jumia这只股票很久了。去年Jumia刚上市我就开始关注了,并且在上市后第一波行情中赚了一笔。但是没过多久Jumia就遭遇香橼做空,加上几次财报数据都很难看,所以股价一泻千里,一路暴跌加阴跌,股价从上市初最高点49.77美元一路跌到最低点2.15美元才开始企稳反弹,这期间的累计跌幅高达95%以上!这段时间我先是多头头寸亏损很大,好在后来承认错误平仓止损并且转为做空,才大幅收复损失。在Jumia股价触及2.15美元低点以后就开始了企稳反弹之路,我这时又转为做多。最近一次财报大跌时我清仓了多头头寸,改为空仓观望,因为我觉得可能还会持续阴跌一段时间才会再次起飞。但我并没有反手做空,因为我觉得Jumia的基本面即将迎来困境反转,此时做空风险无限大,即使短线看空也不能实盘做空。事实证明我没有贸然做空的决策是正确的。因为大多数人预期的阴跌并没有到来,反而股价连续暴涨。我一看不对劲,实际走势和大多数人的预期完全是反着来,于是我不再空仓等待,在财报大跌后连续大涨三天时果断介入,满仓做多。到现在为止已经翻了一倍多,因为我是满仓做多,所以我的美股账户总资产也跟着翻了一倍多。如果我是轻仓参与,虽然股价翻倍,但是我的美股账户总资产也不可能翻倍,这就是我下面要强调的关键时刻要敢于重仓做多的原因。因为对自己的选股有足够的信心,所以才敢满仓做多。我是打算持有几年以上的,即使短期跌了也无所谓。并不是所有的重仓或者满仓都是赌博。轻仓者永远聪明但是永远错过,只有敢于重仓者才能吃到大肉!是否敢于重仓,关键在选股能力。说到选股,不同的人有不同的观点。有的人喜欢价值投资中的基本面选股,有的人喜欢趋势投资中的技术面选股。不能简单说孰优孰劣,本姑娘觉得各有千秋吧,这两种选股","text":"$Jumia Technologies AG(JMIA)$本人关注Jumia这只股票很久了。去年Jumia刚上市我就开始关注了,并且在上市后第一波行情中赚了一笔。但是没过多久Jumia就遭遇香橼做空,加上几次财报数据都很难看,所以股价一泻千里,一路暴跌加阴跌,股价从上市初最高点49.77美元一路跌到最低点2.15美元才开始企稳反弹,这期间的累计跌幅高达95%以上!这段时间我先是多头头寸亏损很大,好在后来承认错误平仓止损并且转为做空,才大幅收复损失。在Jumia股价触及2.15美元低点以后就开始了企稳反弹之路,我这时又转为做多。最近一次财报大跌时我清仓了多头头寸,改为空仓观望,因为我觉得可能还会持续阴跌一段时间才会再次起飞。但我并没有反手做空,因为我觉得Jumia的基本面即将迎来困境反转,此时做空风险无限大,即使短线看空也不能实盘做空。事实证明我没有贸然做空的决策是正确的。因为大多数人预期的阴跌并没有到来,反而股价连续暴涨。我一看不对劲,实际走势和大多数人的预期完全是反着来,于是我不再空仓等待,在财报大跌后连续大涨三天时果断介入,满仓做多。到现在为止已经翻了一倍多,因为我是满仓做多,所以我的美股账户总资产也跟着翻了一倍多。如果我是轻仓参与,虽然股价翻倍,但是我的美股账户总资产也不可能翻倍,这就是我下面要强调的关键时刻要敢于重仓做多的原因。因为对自己的选股有足够的信心,所以才敢满仓做多。我是打算持有几年以上的,即使短期跌了也无所谓。并不是所有的重仓或者满仓都是赌博。轻仓者永远聪明但是永远错过,只有敢于重仓者才能吃到大肉!是否敢于重仓,关键在选股能力。说到选股,不同的人有不同的观点。有的人喜欢价值投资中的基本面选股,有的人喜欢趋势投资中的技术面选股。不能简单说孰优孰劣,本姑娘觉得各有千秋吧,这两种选股","images":[{"img":"https://static.tigerbbs.com/7241138eb18336a2847d6dc07ac8406f","width":"750","height":"1249"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/393409223","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":911,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":391377957,"gmtCreate":1606491531679,"gmtModify":1703843420106,"author":{"id":"3568479083861646","authorId":"3568479083861646","name":"titeufakina","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568479083861646","authorIdStr":"3568479083861646"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/391377957","repostId":"390064684","repostType":1,"repost":{"id":390064684,"gmtCreate":1605672840142,"gmtModify":1703838916404,"author":{"id":"3502767768442965","authorId":"3502767768442965","name":"话题虎","avatar":"https://static.tigerbbs.com/d418c2def5dc1d094b03270b450f71ce","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3502767768442965","authorIdStr":"3502767768442965"},"themes":[],"title":"【话题】巴菲特卖苹果,重金出击疫苗股!虎友们,跟不跟?","htmlText":"最近,巴菲特的<a href=\"https://laohu8.com/S/BRK.A\">$伯克希尔(BRK.A)$</a> 做了一些调仓: 卖了3000多万股苹果,不过,其实只是减少了3%,苹果占巴菲特组合的比例仍高达47.78%, 大概有9亿多股[捂脸]; 大幅减持黄金、银行股,其中<a href=\"https://laohu8.com/S/WFC\">$富国银行(WFC)$</a> ,坚持比例高达46%; 重金出击疫苗股,市值接近38亿美元,包含:2130万股<a href=\"https://laohu8.com/S/ABBV\">$艾伯维公司(ABBV)$</a> 、370万股<a href=\"https://laohu8.com/S/PFE\">$辉瑞(PFE)$</a> 、2997万股<a href=\"https://laohu8.com/S/BMY\">$施贵宝(BMY)$</a> 、2240万股<a href=\"https://laohu8.com/S/0O14.UK\">$德国默克(0O14.UK)$</a> 。 值得注意的是,此消息来源根据伯克希尔的最近3季度持仓报告,数据具有明显的延迟性。 另一方面,疫苗股利好消息也不断传出。 近日,另一家美国药企莫德纳<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a> 在11月16日,公布了其新冠疫苗III期实验报告,有效率高达94.5%。 随着新冠疫苗研发竞赛的进行,根据世界卫生组织的统计: 目前有12个新冠候选疫苗已经进入III期阶段,且有效性、安全性都比较明朗,到今年年底或明年年初,疫苗即有可能获得FDA或者欧盟批准上市。 .. ... 最后,大家聊一聊: 虎友们,是否打算跟随股神一起出击医药股? 这次股神会在医药股上,大赚特赚吗? 精彩留言","listText":"最近,巴菲特的<a href=\"https://laohu8.com/S/BRK.A\">$伯克希尔(BRK.A)$</a> 做了一些调仓: 卖了3000多万股苹果,不过,其实只是减少了3%,苹果占巴菲特组合的比例仍高达47.78%, 大概有9亿多股[捂脸]; 大幅减持黄金、银行股,其中<a href=\"https://laohu8.com/S/WFC\">$富国银行(WFC)$</a> ,坚持比例高达46%; 重金出击疫苗股,市值接近38亿美元,包含:2130万股<a href=\"https://laohu8.com/S/ABBV\">$艾伯维公司(ABBV)$</a> 、370万股<a href=\"https://laohu8.com/S/PFE\">$辉瑞(PFE)$</a> 、2997万股<a href=\"https://laohu8.com/S/BMY\">$施贵宝(BMY)$</a> 、2240万股<a href=\"https://laohu8.com/S/0O14.UK\">$德国默克(0O14.UK)$</a> 。 值得注意的是,此消息来源根据伯克希尔的最近3季度持仓报告,数据具有明显的延迟性。 另一方面,疫苗股利好消息也不断传出。 近日,另一家美国药企莫德纳<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a> 在11月16日,公布了其新冠疫苗III期实验报告,有效率高达94.5%。 随着新冠疫苗研发竞赛的进行,根据世界卫生组织的统计: 目前有12个新冠候选疫苗已经进入III期阶段,且有效性、安全性都比较明朗,到今年年底或明年年初,疫苗即有可能获得FDA或者欧盟批准上市。 .. ... 最后,大家聊一聊: 虎友们,是否打算跟随股神一起出击医药股? 这次股神会在医药股上,大赚特赚吗? 精彩留言","text":"最近,巴菲特的$伯克希尔(BRK.A)$ 做了一些调仓: 卖了3000多万股苹果,不过,其实只是减少了3%,苹果占巴菲特组合的比例仍高达47.78%, 大概有9亿多股[捂脸]; 大幅减持黄金、银行股,其中$富国银行(WFC)$ ,坚持比例高达46%; 重金出击疫苗股,市值接近38亿美元,包含:2130万股$艾伯维公司(ABBV)$ 、370万股$辉瑞(PFE)$ 、2997万股$施贵宝(BMY)$ 、2240万股$德国默克(0O14.UK)$ 。 值得注意的是,此消息来源根据伯克希尔的最近3季度持仓报告,数据具有明显的延迟性。 另一方面,疫苗股利好消息也不断传出。 近日,另一家美国药企莫德纳$Moderna, Inc.(MRNA)$ 在11月16日,公布了其新冠疫苗III期实验报告,有效率高达94.5%。 随着新冠疫苗研发竞赛的进行,根据世界卫生组织的统计: 目前有12个新冠候选疫苗已经进入III期阶段,且有效性、安全性都比较明朗,到今年年底或明年年初,疫苗即有可能获得FDA或者欧盟批准上市。 .. ... 最后,大家聊一聊: 虎友们,是否打算跟随股神一起出击医药股? 这次股神会在医药股上,大赚特赚吗? 精彩留言","images":[],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/390064684","isVote":2,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"vote":{"id":1185,"gmtBegin":1605672904820,"gmtEnd":1606018483547,"type":1,"upper":1,"title":"你是否看好医药/疫苗股?","choices":[{"id":4450,"sort":1,"name":"看好,相信股神的眼光!","userSize":187,"voted":false},{"id":4451,"sort":2,"name":"不看好,时机未到!","userSize":57,"voted":false}]},"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":774,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":391378275,"gmtCreate":1606491254397,"gmtModify":1703843414027,"author":{"id":"3568479083861646","authorId":"3568479083861646","name":"titeufakina","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568479083861646","authorIdStr":"3568479083861646"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/391378275","repostId":"390450978","repostType":1,"repost":{"id":390450978,"gmtCreate":1605843648994,"gmtModify":1710940121819,"author":{"id":"3528966054893519","authorId":"3528966054893519","name":"小虎说英股","avatar":"https://static.tigerbbs.com/b444754ad4cb8cbfaf0dcb4fb2537c79","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3528966054893519","authorIdStr":"3528966054893519"},"themes":[],"title":"Regal Cinemas Owner in Talks for Rescue Package","htmlText":"This article is from The Wall Street Journal on November 20th, 2020. 小虎说英股 loves The Wall Street Journal[爱你] <a target=\"_blank\" href=\"https://laohu8.com/S/CINE.UK\">$CINEWORLD(CINE.UK)$</a>is negotiating with lenders as it confronts the threat to its business caused by the pandemicRegal Entertainment Group owner Cineworld Group PLC is in talks with investors for financial lifelines after months of empty theaters in the U.S. and U.K. during the coronavirus pandemic, according to people familiar with the matter.One proposal under consideration would supply rescue financing to help Cineworld avoid filing for protection from creditors, some of the people said.Under an alternate proposal, investors would provide a loan to finance an insolvency proceeding, the British equivalent of bankruptc","listText":"This article is from The Wall Street Journal on November 20th, 2020. 小虎说英股 loves The Wall Street Journal[爱你] <a target=\"_blank\" href=\"https://laohu8.com/S/CINE.UK\">$CINEWORLD(CINE.UK)$</a>is negotiating with lenders as it confronts the threat to its business caused by the pandemicRegal Entertainment Group owner Cineworld Group PLC is in talks with investors for financial lifelines after months of empty theaters in the U.S. and U.K. during the coronavirus pandemic, according to people familiar with the matter.One proposal under consideration would supply rescue financing to help Cineworld avoid filing for protection from creditors, some of the people said.Under an alternate proposal, investors would provide a loan to finance an insolvency proceeding, the British equivalent of bankruptc","text":"This article is from The Wall Street Journal on November 20th, 2020. 小虎说英股 loves The Wall Street Journal[爱你] $CINEWORLD(CINE.UK)$is negotiating with lenders as it confronts the threat to its business caused by the pandemicRegal Entertainment Group owner Cineworld Group PLC is in talks with investors for financial lifelines after months of empty theaters in the U.S. and U.K. during the coronavirus pandemic, according to people familiar with the matter.One proposal under consideration would supply rescue financing to help Cineworld avoid filing for protection from creditors, some of the people said.Under an alternate proposal, investors would provide a loan to finance an insolvency proceeding, the British equivalent of bankruptc","images":[{"img":"https://static.tigerbbs.com/10f8170b4855bcb853ec86f587dd12ff"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/390450978","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":393,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":393578747,"gmtCreate":1606339323589,"gmtModify":1703842718797,"author":{"id":"3568479083861646","authorId":"3568479083861646","name":"titeufakina","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568479083861646","authorIdStr":"3568479083861646"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/393578747","repostId":"399737732","repostType":1,"repost":{"id":399737732,"gmtCreate":1606188814726,"gmtModify":1703841508657,"author":{"id":"3568564821331838","authorId":"3568564821331838","name":"牧财鲸_踩不到热点版","avatar":"https://static.tigerbbs.com/0696d009cfc0d2b729160bd74e366dd8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568564821331838","authorIdStr":"3568564821331838"},"themes":[],"title":"分享7个我最常用的美股研究网站。包括筛选器,财报,期权,ETF,IPO,做空,应有尽有。而且免注册!","htmlText":"分享7个我最常用的美股研究网站。包括筛选器,财报,期权,ETF,IPO,做空,应有尽有。而且免费且不需要注册!-01- finviz美股筛选神器。你想要的基本面,技术面,信息面,基本上都会有,而且选项非常全。设置好筛选器后,你还可以根据需要调节成全图表观看,或者全基本面观看,或者多种模式结合。甚至你还可以看到大股东内部仓位变动。-02- barchart这个网站你可以同时查看股票,ETF,期权,期货和外汇。并且不仅能查看美国市场,还能查看加拿大,英国,澳大利亚等国家的市场。我一般会利用这个网站来查看股指期货和高波动率(High Implied Volatility)的期权,从而寻找一些个股的机会。比如你可以点击期权(options),然后左侧选择最活跃期权。接着列表就会按照活跃程度列出个股,同时还会有puts和calls的持仓比例。非常好用。-03- tradingview免费看图表和作图表的网站。你作的图可以储存分享或下载。技术图表爱好者的天堂。同时他还有讨论社区,可以看别人的作图和分析。-04- earningswhispers提前查看知晓公司发布财报的日期和时间。选择日历选项,还可以以日期将公司排序为你呈现。并且还有分析师预测数据,未来指引等数据。-05- money.usnews/funds/etfs了解和筛选美国市场上各种的ETF。包括中国科技ETF,中国互联网ETF等等。上面涵盖关于ETF的所有信息。包括介绍,排名,持仓等等。-06- iposcoop查看近年来在美股市场上市的所有IPO和即将上市的IPO。时间间隔和区间可以任由你的选择。-07- shortsqueeze查看个股被卖空的比例和股数。方便我对个股技术面研究和买入点卖出点的判断。但是这里要提一下,这个网站信息更新比较迟缓。所以卖空数据可能不准确。但目前我又没找到更好的查看这方面数据的网站,所以将就用","listText":"分享7个我最常用的美股研究网站。包括筛选器,财报,期权,ETF,IPO,做空,应有尽有。而且免费且不需要注册!-01- finviz美股筛选神器。你想要的基本面,技术面,信息面,基本上都会有,而且选项非常全。设置好筛选器后,你还可以根据需要调节成全图表观看,或者全基本面观看,或者多种模式结合。甚至你还可以看到大股东内部仓位变动。-02- barchart这个网站你可以同时查看股票,ETF,期权,期货和外汇。并且不仅能查看美国市场,还能查看加拿大,英国,澳大利亚等国家的市场。我一般会利用这个网站来查看股指期货和高波动率(High Implied Volatility)的期权,从而寻找一些个股的机会。比如你可以点击期权(options),然后左侧选择最活跃期权。接着列表就会按照活跃程度列出个股,同时还会有puts和calls的持仓比例。非常好用。-03- tradingview免费看图表和作图表的网站。你作的图可以储存分享或下载。技术图表爱好者的天堂。同时他还有讨论社区,可以看别人的作图和分析。-04- earningswhispers提前查看知晓公司发布财报的日期和时间。选择日历选项,还可以以日期将公司排序为你呈现。并且还有分析师预测数据,未来指引等数据。-05- money.usnews/funds/etfs了解和筛选美国市场上各种的ETF。包括中国科技ETF,中国互联网ETF等等。上面涵盖关于ETF的所有信息。包括介绍,排名,持仓等等。-06- iposcoop查看近年来在美股市场上市的所有IPO和即将上市的IPO。时间间隔和区间可以任由你的选择。-07- shortsqueeze查看个股被卖空的比例和股数。方便我对个股技术面研究和买入点卖出点的判断。但是这里要提一下,这个网站信息更新比较迟缓。所以卖空数据可能不准确。但目前我又没找到更好的查看这方面数据的网站,所以将就用","text":"分享7个我最常用的美股研究网站。包括筛选器,财报,期权,ETF,IPO,做空,应有尽有。而且免费且不需要注册!-01- finviz美股筛选神器。你想要的基本面,技术面,信息面,基本上都会有,而且选项非常全。设置好筛选器后,你还可以根据需要调节成全图表观看,或者全基本面观看,或者多种模式结合。甚至你还可以看到大股东内部仓位变动。-02- barchart这个网站你可以同时查看股票,ETF,期权,期货和外汇。并且不仅能查看美国市场,还能查看加拿大,英国,澳大利亚等国家的市场。我一般会利用这个网站来查看股指期货和高波动率(High Implied Volatility)的期权,从而寻找一些个股的机会。比如你可以点击期权(options),然后左侧选择最活跃期权。接着列表就会按照活跃程度列出个股,同时还会有puts和calls的持仓比例。非常好用。-03- tradingview免费看图表和作图表的网站。你作的图可以储存分享或下载。技术图表爱好者的天堂。同时他还有讨论社区,可以看别人的作图和分析。-04- earningswhispers提前查看知晓公司发布财报的日期和时间。选择日历选项,还可以以日期将公司排序为你呈现。并且还有分析师预测数据,未来指引等数据。-05- money.usnews/funds/etfs了解和筛选美国市场上各种的ETF。包括中国科技ETF,中国互联网ETF等等。上面涵盖关于ETF的所有信息。包括介绍,排名,持仓等等。-06- iposcoop查看近年来在美股市场上市的所有IPO和即将上市的IPO。时间间隔和区间可以任由你的选择。-07- shortsqueeze查看个股被卖空的比例和股数。方便我对个股技术面研究和买入点卖出点的判断。但是这里要提一下,这个网站信息更新比较迟缓。所以卖空数据可能不准确。但目前我又没找到更好的查看这方面数据的网站,所以将就用","images":[{"img":"https://static.tigerbbs.com/4d65e9165a6ba73bcf857fbbd7509dce","width":"1080","height":"763"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/399737732","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":10,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1229,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":393578645,"gmtCreate":1606338858887,"gmtModify":1703842718109,"author":{"id":"3568479083861646","authorId":"3568479083861646","name":"titeufakina","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568479083861646","authorIdStr":"3568479083861646"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/393578645","repostId":"393136887","repostType":1,"repost":{"id":393136887,"gmtCreate":1606244724345,"gmtModify":1703842063506,"author":{"id":"3468322318173915","authorId":"3468322318173915","name":"阳光财经","avatar":"https://static.tigerbbs.com/ae4ab676f150a8d357cb5f3e4956d1a0","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3468322318173915","authorIdStr":"3468322318173915"},"themes":[],"title":"","htmlText":"\n \n \n 美股分析2021年风险前瞻:美股估值历史最高位!2021年会不会迎来系统性风险?\n \n","listText":"美股分析2021年风险前瞻:美股估值历史最高位!2021年会不会迎来系统性风险?","text":"美股分析2021年风险前瞻:美股估值历史最高位!2021年会不会迎来系统性风险?","images":[],"top":1,"highlighted":2,"essential":2,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/393136887","isVote":1,"tweetType":2,"object":{"id":"8996d45defe5411e8639ebe4d09a5caf","tweetId":"393136887","title":"美股分析2021年风险前瞻:美股估值历史最高位!2021年会不会迎来系统性风险?","videoUrl":"http://v.tigerbbs.com/160624472122803ce512d367597e8f61108c42c9bc5f9.mp4","poster":"https://static.tigerbbs.com/b63dfa1c3848a5c84866efb48942a9dd","shareLink":"http://v.tigerbbs.com/160624472122803ce512d367597e8f61108c42c9bc5f9.mp4"},"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":611,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":399296197,"gmtCreate":1606137582219,"gmtModify":1703841070763,"author":{"id":"3568479083861646","authorId":"3568479083861646","name":"titeufakina","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568479083861646","authorIdStr":"3568479083861646"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/399296197","repostId":"390823726","repostType":1,"repost":{"id":390823726,"gmtCreate":1605770401365,"gmtModify":1703839473017,"author":{"id":"3540166583692073","authorId":"3540166583692073","name":"爱投学院","avatar":"https://static.tigerbbs.com/8def4c9b37e078bb8f8421d71f6603d4","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3540166583692073","authorIdStr":"3540166583692073"},"themes":[],"title":"中概股简直涨疯了,这只未来的Youtube,千万别错过!","htmlText":"\n \n \n 大疫情背景下,中概股简直是独领风骚。曾经被大部分人不看好的二次元小破站,如今也崛起成为了多媒体平台帝国了。想知道这是哪只巨大的潜力股吗,点开视频看看吧!<a target=\"_blank\" href=\"https://laohu8.com/S/BILI\">$哔哩哔哩(BILI)$</a> <a target=\"_blank\" href=\"https://laohu8.com/S/GOOG\">$谷歌(GOOG)$</a> <a target=\"_blank\" href=\"https://laohu8.com/S/BABA\">$阿里巴巴(BABA)$</a> 公司于今日发布了未经审计的三季报,营收32.3亿元,同比增长74%,超出预期!本季度,用户日均视频播放量达到创记录的13亿次,同比提升77%。随着社区参与度的持续走高,用户日均使用时长高达81分钟。本季度月均付费用户数同比增长89%达1500万,期待未来的盈利能力不断提升。公司对2020年第四季度收入进行了展望,预计将达到36.0亿元至37.0亿元人民币。爱投学院与老虎联合推出最畅销<a href=\"https://www.laohu8.com/m/space?userId=3540166583692073\" target=\"_blank\">北美投资课程</a>,北美专家手把手教你分析,授之以渔,把财富增值掌握在自己手中。无论美股、港股还是A股,这些经验和方法都非常适用。快来感受原汁原味的北美独立观点,和我们踏上财富自由的旅程。\n \n","listText":"大疫情背景下,中概股简直是独领风骚。曾经被大部分人不看好的二次元小破站,如今也崛起成为了多媒体平台帝国了。想知道这是哪只巨大的潜力股吗,点开视频看看吧!<a target=\"_blank\" href=\"https://laohu8.com/S/BILI\">$哔哩哔哩(BILI)$</a> <a target=\"_blank\" href=\"https://laohu8.com/S/GOOG\">$谷歌(GOOG)$</a> <a target=\"_blank\" href=\"https://laohu8.com/S/BABA\">$阿里巴巴(BABA)$</a> 公司于今日发布了未经审计的三季报,营收32.3亿元,同比增长74%,超出预期!本季度,用户日均视频播放量达到创记录的13亿次,同比提升77%。随着社区参与度的持续走高,用户日均使用时长高达81分钟。本季度月均付费用户数同比增长89%达1500万,期待未来的盈利能力不断提升。公司对2020年第四季度收入进行了展望,预计将达到36.0亿元至37.0亿元人民币。爱投学院与老虎联合推出最畅销<a href=\"https://www.laohu8.com/m/space?userId=3540166583692073\" target=\"_blank\">北美投资课程</a>,北美专家手把手教你分析,授之以渔,把财富增值掌握在自己手中。无论美股、港股还是A股,这些经验和方法都非常适用。快来感受原汁原味的北美独立观点,和我们踏上财富自由的旅程。","text":"大疫情背景下,中概股简直是独领风骚。曾经被大部分人不看好的二次元小破站,如今也崛起成为了多媒体平台帝国了。想知道这是哪只巨大的潜力股吗,点开视频看看吧!$哔哩哔哩(BILI)$ $谷歌(GOOG)$ $阿里巴巴(BABA)$ 公司于今日发布了未经审计的三季报,营收32.3亿元,同比增长74%,超出预期!本季度,用户日均视频播放量达到创记录的13亿次,同比提升77%。随着社区参与度的持续走高,用户日均使用时长高达81分钟。本季度月均付费用户数同比增长89%达1500万,期待未来的盈利能力不断提升。公司对2020年第四季度收入进行了展望,预计将达到36.0亿元至37.0亿元人民币。爱投学院与老虎联合推出最畅销北美投资课程,北美专家手把手教你分析,授之以渔,把财富增值掌握在自己手中。无论美股、港股还是A股,这些经验和方法都非常适用。快来感受原汁原味的北美独立观点,和我们踏上财富自由的旅程。","images":[{"img":"https://static.tigerbbs.com/10de52ca8e448635f4ae456a79adb176","width":"0","height":"0"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/390823726","isVote":1,"tweetType":2,"object":{"id":"c2c850deb4c94b898aa42de7d6a844c1","tweetId":"390823726","videoUrl":"https://1254107296.vod2.myqcloud.com/27e1f7ecvodtransgzp1254107296/9405da815285890810101550774/v.f30.mp4","poster":"https://static.tigerbbs.com/10de52ca8e448635f4ae456a79adb176"},"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1011,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":399207835,"gmtCreate":1606136255327,"gmtModify":1703841061425,"author":{"id":"3568479083861646","authorId":"3568479083861646","name":"titeufakina","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568479083861646","authorIdStr":"3568479083861646"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/399207835","repostId":"307533803","repostType":1,"repost":{"id":307533803,"gmtCreate":1605589645502,"gmtModify":1703838449425,"author":{"id":"3497328009582754","authorId":"3497328009582754","name":"桃李春风益点财","avatar":"https://static.tigerbbs.com/dc8827e0d2ccb8087a4e15cbe447ad5c","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3497328009582754","authorIdStr":"3497328009582754"},"themes":[],"title":"美国疫苗即将上市,中国暗自发力,谁将成为全球疫情终结者?","htmlText":"\n \n \n 这次疫苗真的要来了。昨夜,Moderna<a target=\"_blank\" href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a> 宣布,他们研发的疫苗有效率高达94.5%。上周,辉瑞<a target=\"_blank\" href=\"https://laohu8.com/S/PFE\">$辉瑞(PFE)$</a> 公司和德国生物技术公司BioNTech<a target=\"_blank\" href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a> 表示,他们的疫苗在预防新冠方面的效果超过90%,比普通流感疫苗70%的有效率足足高出20%!疫苗捷报频传,这是否意味着我们翘首以盼的疫苗即将问世?疫苗分发的时间表出来了吗?其安全性和有效性方面是否让人放心?对于这几个问题,我们采访了The Pinea Group 的 CEO 和首席执行官马蓓女士。\n \n","listText":"这次疫苗真的要来了。昨夜,Moderna<a target=\"_blank\" href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a> 宣布,他们研发的疫苗有效率高达94.5%。上周,辉瑞<a target=\"_blank\" href=\"https://laohu8.com/S/PFE\">$辉瑞(PFE)$</a> 公司和德国生物技术公司BioNTech<a target=\"_blank\" href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a> 表示,他们的疫苗在预防新冠方面的效果超过90%,比普通流感疫苗70%的有效率足足高出20%!疫苗捷报频传,这是否意味着我们翘首以盼的疫苗即将问世?疫苗分发的时间表出来了吗?其安全性和有效性方面是否让人放心?对于这几个问题,我们采访了The Pinea Group 的 CEO 和首席执行官马蓓女士。","text":"这次疫苗真的要来了。昨夜,Moderna$Moderna, Inc.(MRNA)$ 宣布,他们研发的疫苗有效率高达94.5%。上周,辉瑞$辉瑞(PFE)$ 公司和德国生物技术公司BioNTech$BioNTech SE(BNTX)$ 表示,他们的疫苗在预防新冠方面的效果超过90%,比普通流感疫苗70%的有效率足足高出20%!疫苗捷报频传,这是否意味着我们翘首以盼的疫苗即将问世?疫苗分发的时间表出来了吗?其安全性和有效性方面是否让人放心?对于这几个问题,我们采访了The Pinea Group 的 CEO 和首席执行官马蓓女士。","images":[{"img":"https://static.tigerbbs.com/6a10924389eb4ce37186655b93b19a85","width":"0","height":"0"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/307533803","isVote":1,"tweetType":2,"object":{"id":"8679068a5feb40f7896519ca2eb17913","tweetId":"307533803","videoUrl":"https://1254107296.vod2.myqcloud.com/27e1f7ecvodtransgzp1254107296/655bc3755285890809944129364/v.f30.mp4","poster":"https://static.tigerbbs.com/6a10924389eb4ce37186655b93b19a85"},"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1006,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":399204340,"gmtCreate":1606135977780,"gmtModify":1703841059355,"author":{"id":"3568479083861646","authorId":"3568479083861646","name":"titeufakina","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568479083861646","authorIdStr":"3568479083861646"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/399204340","repostId":"399806024","repostType":1,"repost":{"id":399806024,"gmtCreate":1606071924662,"gmtModify":1703840766606,"author":{"id":"3568528271227724","authorId":"3568528271227724","name":"三藏的财富频道","avatar":"https://static.tigerbbs.com/e56a036257cba67506166ea587b3fbb8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568528271227724","authorIdStr":"3568528271227724"},"themes":[],"title":"","htmlText":"\n \n \n 与大家一起复盘一下ARK对冲基金的投资报告复盘,抄作业的朋友看过来~大家喜欢三藏的视频不要忘记关注,点赞加评论哦! 感谢大家! $Ark Fintech Innovation ETF(ARKF)$ $Ark Restaurants Corp(ARKR)$ $ARK Web x.0 ETF(ARKW)$\n \n","listText":"与大家一起复盘一下ARK对冲基金的投资报告复盘,抄作业的朋友看过来~大家喜欢三藏的视频不要忘记关注,点赞加评论哦! 感谢大家! $Ark Fintech Innovation ETF(ARKF)$ $Ark Restaurants Corp(ARKR)$ $ARK Web x.0 ETF(ARKW)$","text":"与大家一起复盘一下ARK对冲基金的投资报告复盘,抄作业的朋友看过来~大家喜欢三藏的视频不要忘记关注,点赞加评论哦! 感谢大家! $Ark Fintech Innovation ETF(ARKF)$ $Ark Restaurants Corp(ARKR)$ $ARK Web x.0 ETF(ARKW)$","images":[],"top":1,"highlighted":2,"essential":2,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/399806024","isVote":1,"tweetType":2,"object":{"id":"d600af7974ff469f8843121fd511da15","tweetId":"399806024","title":"ARK行业白皮书 2020 年终回顾!为何如此看好特斯拉? Cathie Wood目光独到,电车行业绝对多头!最值得抄的作业!","videoUrl":"http://v.tigerbbs.com/160607192197495f86d3c6779c8e89a8e42a08939c2f9.mp4","poster":"https://static.tigerbbs.com/405380e6dd722b75b3dc46b8ea4783ee","shareLink":"http://v.tigerbbs.com/160607192197495f86d3c6779c8e89a8e42a08939c2f9.mp4"},"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1074,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":399152216,"gmtCreate":1606044996635,"gmtModify":1703840729215,"author":{"id":"3568479083861646","authorId":"3568479083861646","name":"titeufakina","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568479083861646","authorIdStr":"3568479083861646"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/399152216","repostId":"307125783","repostType":1,"repost":{"id":307125783,"gmtCreate":1605518907842,"gmtModify":1703837951621,"author":{"id":"3503452965237041","authorId":"3503452965237041","name":"美股研究社","avatar":"https://static.tigerbbs.com/a239c7906133df1f3817d0746a8a0ba1","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3503452965237041","authorIdStr":"3503452965237041"},"themes":[],"title":"股神“偏爱”这三只股,投资者该“抄作业”吗?","htmlText":"作为伯克希尔·哈撒韦公司的首席执行官,沃伦·巴菲特已经养成了不太喜欢科技股的名声,他更喜欢专注于不那么复杂的业务。但巴菲特近年来已开始投资一些科技股,顶级科技投资一直是伯克希尔投资组合中表现最佳的资产之一。考虑到这一点,我们请三位《Motley Fool》撰稿人简要介绍了一些由巴菲特支持、值得马上买进的科技股。继续读下去,看看他们为什么认为StoneCo(STNE)、亚马逊(AMZN)和苹果(AAPL)具备成为赢家的条件。伯克希尔最热门的股票之一<a target=\"_blank\" href=\"https://laohu8.com/S/STNE\">$StoneCo(STNE)$</a> Keith Noonan(StoneCo):在这家巴西金融科技公司两年前首次公开募股时,巴菲特和伯克希尔哈撒韦公司在StoneCo建立了相当大的头寸。该公司股价已较每股24美元的IPO价格上涨了约170%,长期来看,该股仍有诱人的上行空间。与美国、欧洲和亚洲大部分地区相比,巴西支付处理服务的使用率仍然较低,但随着巴西人越来越依赖银行卡和手机支付而不是现金进行日常交易,这一领域仍有很大的增长空间。该公司还有望从巴西和其他拉美国家在线零售的增长中获益。摩根大通2019年的一份报告估计,电子商务仅占巴西整体零售市场的3.2%。电子商务的长期增长将刺激支付处理服务的需求,StoneCo已经看到了这一趋势的好处。尽管冠状病毒导致实体零售店暂时关闭,客流量减少,但该公司仍实现了强劲增长,整体业绩开始改善,门店运营接近正常水平。第三季度,StoneCo成功增加了6.3万名新商户客户,调整后通过该公司平台进行的支付总额同比飙升48%。同期调整后的销售额同比增长46%。该公司应该会继续保持强劲增长,因为它将在其支付平台吸引更多的商家合作伙伴,并从整个平台的交易总额中抽取一小部分。StoneCo的表现","listText":"作为伯克希尔·哈撒韦公司的首席执行官,沃伦·巴菲特已经养成了不太喜欢科技股的名声,他更喜欢专注于不那么复杂的业务。但巴菲特近年来已开始投资一些科技股,顶级科技投资一直是伯克希尔投资组合中表现最佳的资产之一。考虑到这一点,我们请三位《Motley Fool》撰稿人简要介绍了一些由巴菲特支持、值得马上买进的科技股。继续读下去,看看他们为什么认为StoneCo(STNE)、亚马逊(AMZN)和苹果(AAPL)具备成为赢家的条件。伯克希尔最热门的股票之一<a target=\"_blank\" href=\"https://laohu8.com/S/STNE\">$StoneCo(STNE)$</a> Keith Noonan(StoneCo):在这家巴西金融科技公司两年前首次公开募股时,巴菲特和伯克希尔哈撒韦公司在StoneCo建立了相当大的头寸。该公司股价已较每股24美元的IPO价格上涨了约170%,长期来看,该股仍有诱人的上行空间。与美国、欧洲和亚洲大部分地区相比,巴西支付处理服务的使用率仍然较低,但随着巴西人越来越依赖银行卡和手机支付而不是现金进行日常交易,这一领域仍有很大的增长空间。该公司还有望从巴西和其他拉美国家在线零售的增长中获益。摩根大通2019年的一份报告估计,电子商务仅占巴西整体零售市场的3.2%。电子商务的长期增长将刺激支付处理服务的需求,StoneCo已经看到了这一趋势的好处。尽管冠状病毒导致实体零售店暂时关闭,客流量减少,但该公司仍实现了强劲增长,整体业绩开始改善,门店运营接近正常水平。第三季度,StoneCo成功增加了6.3万名新商户客户,调整后通过该公司平台进行的支付总额同比飙升48%。同期调整后的销售额同比增长46%。该公司应该会继续保持强劲增长,因为它将在其支付平台吸引更多的商家合作伙伴,并从整个平台的交易总额中抽取一小部分。StoneCo的表现","text":"作为伯克希尔·哈撒韦公司的首席执行官,沃伦·巴菲特已经养成了不太喜欢科技股的名声,他更喜欢专注于不那么复杂的业务。但巴菲特近年来已开始投资一些科技股,顶级科技投资一直是伯克希尔投资组合中表现最佳的资产之一。考虑到这一点,我们请三位《Motley Fool》撰稿人简要介绍了一些由巴菲特支持、值得马上买进的科技股。继续读下去,看看他们为什么认为StoneCo(STNE)、亚马逊(AMZN)和苹果(AAPL)具备成为赢家的条件。伯克希尔最热门的股票之一$StoneCo(STNE)$ Keith Noonan(StoneCo):在这家巴西金融科技公司两年前首次公开募股时,巴菲特和伯克希尔哈撒韦公司在StoneCo建立了相当大的头寸。该公司股价已较每股24美元的IPO价格上涨了约170%,长期来看,该股仍有诱人的上行空间。与美国、欧洲和亚洲大部分地区相比,巴西支付处理服务的使用率仍然较低,但随着巴西人越来越依赖银行卡和手机支付而不是现金进行日常交易,这一领域仍有很大的增长空间。该公司还有望从巴西和其他拉美国家在线零售的增长中获益。摩根大通2019年的一份报告估计,电子商务仅占巴西整体零售市场的3.2%。电子商务的长期增长将刺激支付处理服务的需求,StoneCo已经看到了这一趋势的好处。尽管冠状病毒导致实体零售店暂时关闭,客流量减少,但该公司仍实现了强劲增长,整体业绩开始改善,门店运营接近正常水平。第三季度,StoneCo成功增加了6.3万名新商户客户,调整后通过该公司平台进行的支付总额同比飙升48%。同期调整后的销售额同比增长46%。该公司应该会继续保持强劲增长,因为它将在其支付平台吸引更多的商家合作伙伴,并从整个平台的交易总额中抽取一小部分。StoneCo的表现","images":[{"img":"https://static.tigerbbs.com/e5b01d0286933483e1f024d482ed201e","width":"640","height":"360"}],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/307125783","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":983,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":399152806,"gmtCreate":1606044855605,"gmtModify":1703840729042,"author":{"id":"3568479083861646","authorId":"3568479083861646","name":"titeufakina","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568479083861646","authorIdStr":"3568479083861646"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/399152806","repostId":"2084281420","repostType":4,"repost":{"id":"2084281420","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1062363208","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1605860434,"share":"https://www.laohu8.com/m/news/2084281420?lang=&edition=full","pubTime":"2020-11-20 16:20","market":"other","language":"en","title":"Novartis signs $50 mln deal for Mesoblast cell therapy for COVID, beyond","url":"https://stock-news.laohu8.com/highlight/detail?id=2084281420","media":"Reuters","summary":"ZURICH, Nov 20 (Reuters) - Novartis aims to boost its respiratory treatment portfolio with a $50 mil","content":"<p>ZURICH, Nov 20 (Reuters) - Novartis aims to boost its respiratory treatment portfolio with a $50 million deal for an off-the-shelf cell therapy from Mesoblast that it hopes to deploy for COVID-19 patients as well as others suffering from respiratory distress.</p><p>The Swiss drugmaker's deal with Australia-based Mesoblast secures rights to develop, commercialize and manufacture Remestemcel-L for treating acute respiratory distress syndrome <a href=\"https://laohu8.com/S/ARDS\">$(ARDS)$</a>, including that associated with COVID-19, for which the therapy is currently in late-stage trials.</p><p>While the therapy has shown promise in COVID-19 patients -- -- in a compassionate use programme in March in 12 patients, Remestemcel-L was associated with an 83% survival rate -- Novartis wants the medicine for beyond the pandemic, too, to help patients who in normal times also land in the hospital with ARDS and often die.</p><p>\"It has the potential to be the first treatment for the most critically ill ARDS patients, and it provides us with an opportunity to apply years of specialized experience directly to the work of saving lives,\" Novartis's chief drug developer, John Tsai, said on Friday.</p><p>Unlike Kymriah, Novartis's cancer cell therapy, Remestemcel-L does not have to be tailored for each patient. Once the deal is closed, Novartis said it is planning to help Mesoblast work on quality attributes of the therapy so it meets U.S. Food and Drug Administration requirements necessary for late-stage trial beyond COVID-19.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis signs $50 mln deal for Mesoblast cell therapy for COVID, beyond</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis signs $50 mln deal for Mesoblast cell therapy for COVID, beyond\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1062363208\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2020-11-20 16:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ZURICH, Nov 20 (Reuters) - Novartis aims to boost its respiratory treatment portfolio with a $50 million deal for an off-the-shelf cell therapy from Mesoblast that it hopes to deploy for COVID-19 patients as well as others suffering from respiratory distress.</p><p>The Swiss drugmaker's deal with Australia-based Mesoblast secures rights to develop, commercialize and manufacture Remestemcel-L for treating acute respiratory distress syndrome <a href=\"https://laohu8.com/S/ARDS\">$(ARDS)$</a>, including that associated with COVID-19, for which the therapy is currently in late-stage trials.</p><p>While the therapy has shown promise in COVID-19 patients -- -- in a compassionate use programme in March in 12 patients, Remestemcel-L was associated with an 83% survival rate -- Novartis wants the medicine for beyond the pandemic, too, to help patients who in normal times also land in the hospital with ARDS and often die.</p><p>\"It has the potential to be the first treatment for the most critically ill ARDS patients, and it provides us with an opportunity to apply years of specialized experience directly to the work of saving lives,\" Novartis's chief drug developer, John Tsai, said on Friday.</p><p>Unlike Kymriah, Novartis's cancer cell therapy, Remestemcel-L does not have to be tailored for each patient. Once the deal is closed, Novartis said it is planning to help Mesoblast work on quality attributes of the therapy so it meets U.S. Food and Drug Administration requirements necessary for late-stage trial beyond COVID-19.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MSB.AU":"MESOBLAST LTD","NVS":"诺华"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2084281420","content_text":"ZURICH, Nov 20 (Reuters) - Novartis aims to boost its respiratory treatment portfolio with a $50 million deal for an off-the-shelf cell therapy from Mesoblast that it hopes to deploy for COVID-19 patients as well as others suffering from respiratory distress.The Swiss drugmaker's deal with Australia-based Mesoblast secures rights to develop, commercialize and manufacture Remestemcel-L for treating acute respiratory distress syndrome $(ARDS)$, including that associated with COVID-19, for which the therapy is currently in late-stage trials.While the therapy has shown promise in COVID-19 patients -- -- in a compassionate use programme in March in 12 patients, Remestemcel-L was associated with an 83% survival rate -- Novartis wants the medicine for beyond the pandemic, too, to help patients who in normal times also land in the hospital with ARDS and often die.\"It has the potential to be the first treatment for the most critically ill ARDS patients, and it provides us with an opportunity to apply years of specialized experience directly to the work of saving lives,\" Novartis's chief drug developer, John Tsai, said on Friday.Unlike Kymriah, Novartis's cancer cell therapy, Remestemcel-L does not have to be tailored for each patient. Once the deal is closed, Novartis said it is planning to help Mesoblast work on quality attributes of the therapy so it meets U.S. Food and Drug Administration requirements necessary for late-stage trial beyond COVID-19.","news_type":1},"isVote":1,"tweetType":1,"viewCount":602,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}